

## CF Reference List

(compiled between September 2020 – January 2021)

### Adults & Adolescents

- Frayman KB., Chin M., Sawyer SM., Bell SC.**  
Sexual and reproductive health in cystic fibrosis  
*Current Opinion in Pulmonary Medicine* 2020; 26: 685 - 695
- Healey N.**  
The gender gap in cystic fibrosis  
*Nature* 2020; 583: S10 - S11
- Lam GY., Goodwin J., Wilcox P., Quon BS.**  
Worsening pulmonary outcomes during sex reassignment therapy in a transgender female with cystic fibrosis (CF) and asthma/allergic bronchopulmonary aspergillosis: a case report  
*BMC Pulmonary Medicine* 2020; 20: ArtNo.1:234
- Leech MM., Stransky OM., Talabi MB., Borrero S., Roe AH., Kazmerski TM.**  
Exploring the reproductive decision support needs and preferences of women with cystic fibrosis  
*Contraception* 2021; 103: 32 - 37
- Onofri A., Broomfield A., Tan HL.**  
Transition to Adult Care in Children on Long-Term Ventilation  
*Frontiers in Pediatrics* 2020; 8: ArtNo: 548839
- Profka E., Rodari G., Giacchetti F., Berrettini A., Manzoni G., Dacco V., Arosio M., Giavoli C., Colombo C.**  
A case of testicular atrophy associated with cystic fibrosis  
*Endocrinology Diabetes and Metabolism Case Reports* 2020; : ArtNo: 200095
- Sawyer A., Cavalheri V., Jenkins S., Wood J., Cecins N., Bear N., Singh B., Gucciardi D., Hill K.**  
High-Intensity Interval Training Is Effective at Increasing Exercise Endurance Capacity and Is Well Tolerated by Adults with Cystic Fibrosis  
*Journal of Clinical Medicine* 2020; 9: ArtNo.10:3098
- Taylor-Cousar JL.**  
CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis  
*Journal of Clinical Medicine* 2020; 9: 9:2706
- Taylor-Robinson D., Schluter DK., Diggle PJ., Barrett JK.**  
Explaining the Sex Effect on Survival in Cystic Fibrosis: a Joint Modeling Study of UK Registry Data  
*Epidemiology* 2020; 31: 872 - 879
- Willis LD.**  
Transition From Pediatric to Adult Care for Young Adults With Chronic Respiratory Disease  
*Respiratory Care* 2020; 65: 1916 - 1922

### Animal Model

- Brea D., Soler L., Fleurot I., Melo S., Chevalyere C., Berri M., Labas V., Teixeira-Gomes AP., Pujo J., Cenac N., Bahr A., Klymiuk N., Guillon A., Si-Tahar M., Caballero I.**  
Intrinsic alterations in peripheral neutrophils from cystic fibrosis newborn piglets  
*Journal of Cystic Fibrosis* 2020; 19: 830 - 836
- Corey DA., Rymut SM., Kelley TJ.**  
Alleviation of depression-like behavior in a cystic fibrosis mouse model by Hdac6 depletion  
*Scientific Reports* 2020; 10: 1:16278
- McHugh DR., Cotton CU., Hodges CA.**  
Synergy between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations  
*International Journal of Molecular Sciences* 2021; 22: 1:344
- Sharma J., Abbott J., Klaskala L., Zhao G., Birket SE., Rowe SM.**  
A Novel G542X CFTR Rat Model of Cystic Fibrosis Is Sensitive to Nonsense Mediated Decay  
*Frontiers in Physiology* 2020; 11: ArtNo: 611294

- Tang YH., Yan ZY., Lin S., Huntemann ED., Feng ZH., Park SY., Sun XS., Yuen E., Engelhardt JF.**  
Repeat Dosing of AAV2.5T to Ferret Lungs Elicits an Antibody Response That Diminishes Transduction in an Age-Dependent Manner  
*Molecular Therapy-Methods & Clinical Development* 2020; 19: 186 - 200

### Antimicrobials

- Akkerman-Nijland AM., Grasmeyer F., Kerstjens HAM., Frijlink HW., van der Vaart H., Vonk JM., Hagedoorn P., Rottier BL., Koppelman GH., Akkerman OW.**  
Colistin dry powder inhalation with the Twincer (TM): An effective and more patient friendly alternative to nebulization  
*PLoS One* 2020; 15: 9:e0239658
- Allobawi R., Ghelani DP., Schneider-Futschik EK.**  
Metabolomic Description of Ivacaftor Elevating Polymyxin B Mediated Antibacterial Activity in Cystic Fibrosis *Pseudomonas aeruginosa*  
*ACS Pharmacology & Translational Science* 2020; 3: 433 - 443
- Ansari AW., Sharif-Askari FS., Jayakumar MN., Mohammed AK., Sharif-Askari NS., Venkatachalam T., Mahboub B., Schmidt RE., Hamoudi RA., Halwani R., Hamid Q.**  
Azithromycin Differentially Alters TCR-Activated Helper T Cell Subset Phenotype and Effector Function  
*Frontiers in Immunology* 2020; 11: ArtNo: 556579
- Batchelder HR., Story-Roller E., Lloyd EP., Kaushik A., Bigelow KM., Maggioncalda EC., Nuermberger EL., Lamichhane G., Townsend CA.**  
Development of a penem antibiotic against *Mycobacteroides abscessus*  
*Communications Biology* 2020; 3: 1:741
- Bell J., Alexander L., Carson J., Crossan A., McCaughan J., Mills H., O'Neill D., Moore JE., Millar BC.**  
Nebuliser hygiene in cystic fibrosis: evidence-based recommendations  
*Breathe* 2020; 16: ArtNo. 2:19032
- Boyle M., Mulrennan S., Morey S., Vekaria S., Popowicz N., Tai A.**  
Mepolizumab use in cystic fibrosis-associated allergic bronchopulmonary aspergillosis  
*Respirology Case Reports* 2021; 9: 1:e00696
- Bui S., Facchin A., Ha P., Bouchet S., Leroux S., Nacka F., Fayon M., Jacqz-Aigrain E.**  
Population pharmacokinetics of ceftazidime in critically ill children: impact of cystic fibrosis  
*Journal of Antimicrobial Chemotherapy* 2020; 75: 2232 - 2239
- Cabak A., Hovold G., Petersson AC., Ramstedt M., Pahlman LI.**  
Activity of airway antimicrobial peptides against cystic fibrosis pathogens  
*Pathogens and Disease* 2020; 78: 7:ftaa048
- Cavalier JF., Spilling CD., Durand T., Camoin L., Canaan S.**  
Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery  
*European Journal of Medicinal Chemistry* 2021; 209: ArtNo: 112908
- Chai GH., Hassan A., Meng T., Lou LH., Ma J., Simmers R., Zhou L., Rubin BK., Zhou Q., Longest PW., Hindle M., Xu QG.**  
Dry powder aerosol containing muco-inert particles for excipient enhanced growth pulmonary drug delivery  
*Nanomedicine-Nanotechnology Biology and Medicine* 2020; 29: ArtNo: 102262
- Chan BK., Stanley G., Modak M., Koff JL., Turner PE.**  
Bacteriophage therapy for infections in CF  
*Pediatric Pulmonology* 2021; 56:
- Chan HT., Ku H., Low YP., Batinovic S., Kabwe M., Petrovski S., Tucci J.**  
Characterization of Novel Lytic Bacteriophages of *Achromobacter marplantis* Isolated from a Pneumonia Patient  
*Viruses* 2020; 12: 10:1138

- Cogen JD., Faino AV., Onchiri F., Hoffman LR., Kronman MP., Nelson M., Nichols DP., Rosenfeld M., VanDevanter DR., Gibson RL.**  
Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations  
*Annals of the American Thoracic Society* 2020; 17: 1590 - 1598
- Daley CL., Iaccarino JM., Lange C., Cambau E., Wallace RJ., Andrejak C., Bottger EC., Brozek J., Griffith DE., Guglielmetti L., Huitt GA., Knight SL., Leitman P., Marras TK., Olivier KN., Santin M., Stout JE., Tortoli E., et al**  
Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline  
*Clinical Infectious Diseases* 2020; 71: 905 - 913
- Damar-Celik D., Norskov-Lauritsen N., Ozbek-Celik B.**  
Comparative in vitro activities of meropenem in combination with colistin, levofloxacin, or chloramphenicol against *Achromobacter xylosoxidans* strains isolated from patients with cystic fibrosis  
*Journal of Global Antimicrobial Resistance* 2020; 22: 713 - 717
- El-sayed NR., Samir R., Abdel-Hafez LJM., Ramadan MA.**  
Olive Leaf Extract Modulates Quorum Sensing Genes and Biofilm Formation in Multi-Drug Resistant *Pseudomonas aeruginosa*  
*Antibiotics* 2020; 9: 5:26
- Ghodake V., Vishwakarma J., Vavilala SL., Patravale V.**  
Cefoperazone sodium liposomal formulation to mitigate *P. aeruginosa* biofilm in cystic fibrosis infection: A QbD approach  
*International Journal of Pharmaceutics* 2020; 587: ArtNo: 119696
- Goudarzi SM., Ali AA., Modaresi M., Ghazanfari T.**  
Anti-Bacterial vs. Anti-Biofilm Effects of Azithromycin on *Pseudomonas aeruginosa* Isolates from Cystic Fibrosis Patients  
*Iranian Journal of Pediatrics* 2020; 30: Art No. 5:e101
- Hanusch B., Brinkmann F., Mayorandan S., Chobanyan-Jurgens K., Wiemers A., Jansen K., Ballmann M., Schmidt-Choudhury A., Bollenbach A., Derichs N., Tsikas D., Lucke T.**  
Local and Systemic Alterations of the L-Arginine/Nitric Oxide Pathway in Sputum, Blood, and Urine of Pediatric Cystic Fibrosis Patients and Effects of Antibiotic Treatment  
*Journal of Clinical Medicine* 2020; 9: 12:3802
- Hewer SCL., Smyth AR., Brown M., Jones AP., Hickey H., Kenna D., Ashby D., Thompson A., Williamson PR.**  
Intravenous versus oral antibiotics for eradication of *Pseudomonas aeruginosa* in cystic fibrosis (TORPEDO-CF): a randomised controlled trial  
*Lancet Respiratory Medicine* 2020; 8: 975 - 986
- Ho DK., De Rossi C., Loretz B., Murgia X., Lehr CM.**  
Itaconic Acid Increases the Efficacy of Tobramycin against *Pseudomonas*  
*Pharmaceutics* 2020; 12: ArtNo 691
- Hurley MN., Smith S., Forrester DL., Smyth AR.**  
Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2020; : 7:CD008037
- Jaikumpun P., Ruksakiet K., Stercz B., Pallinger E., Steward M., Lohinai Z., Dobay O., Zsembery A.**  
Antibacterial Effects of Bicarbonate in Media Modified to Mimic Cystic Fibrosis Sputum  
*International Journal of Molecular Sciences* 2020; 21: 22:8614
- Kosztolowicz T., Metzler R., Wasik S., Arabski M.**  
Modelling experimentally measured of ciprofloxacin antibiotic diffusion in *Pseudomonas aeruginosa* biofilm formed in artificial sputum medium  
*PLoS One* 2020; 15: 12:e0243003
- Li YZ., Xiao P., Wang YL., Hao Y.**  
Mechanisms and Control Measures of Mature Biofilm Resistance to Antimicrobial Agents in the Clinical Context  
*ACS Omega* 2020; 5: 22684 - 22690
- Longenecker RJ., Gu RD., Homan J., Kil J.**  
A Novel Mouse Model of Aminoglycoside-Induced Hyperacusis and Tinnitus  
*Frontiers in Neuroscience* 2020; 14: ArtNo: 561185
- Moore JE., Moore RE., Bell J., Millar BC.**  
Importance of Nebulizer Drying for Patients With Cystic Fibrosis  
*Respiratory Care* 2020; 65: 1443 - 1450
- Nelson MT., Wolter DJ., Eng A., Weiss EJ., Vo AT., Brittnacher MJ., Hayden HS., Ravishankar S., Bautista G., Ratjen A., Blackledge M., McNamara S., Nay L., Majors C., Miller SI., Borenstein E., Simon RH., LiPuma JJ., Hoffman LR.**  
Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome  
*Thorax* 2020; 75: 780 - 790
- O'Shaughnessy M., McCarron P., Viganor L., McCann M., Devereux M., Howe O.**  
The Antibacterial and Anti-Biofilm Activity of Metal Complexes Incorporating 3,6,9-Trioxaundecanedioate and 1,10-Phenanthroline Ligands in Clinical Isolates of *Pseudomonas aeruginosa* from Irish Cystic Fibrosis Patients  
*Antibiotics* 2020; 9: 10:674
- Patel N., Swavey S., Robinson J.**  
A Cationic Porphyrin, ZnPor, Disassembles *Pseudomonas aeruginosa* Biofilm Matrix, Kills Cells Directly, and Enhances Antibiotic Activity of Tobramycin  
*Antibiotics-basel* 2020; 9: 12:875
- Poerio N., De Santis F., Rossi A., Ranucci S., De Fino I., Henriques A., D'Andrea MM., Ciciriello F., Lucidi V., Nisini R., Bragonzi A., Fraziano M.**  
Liposomes Loaded With Phosphatidylinositol 5-Phosphate Improve the Antimicrobial Response to *Pseudomonas aeruginosa* Impaired Macrophages From Cystic Fibrosis Patients and Limit Airway Inflammatory Response  
*Frontiers in Immunology* 2020; 11: ArtNo: 532225
- Raghuvanshi R., Vasco K., Vazquez-Baeza Y., Jiang LJ., Morton JT., Li DX., Gonzalez A., Goldasich LD., Humphrey G., Ackermann G., Swafford AD., Conrad D., Knight R., Dorrestein PC., Quinn RA.**  
High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic Therapy  
*Msystems* 2020; 5: 3:e00292-20
- Ragno R., Papa R., Patsilinos A., Vrenna G., Garzoli S., Tuccio V., Fiscarelli E., Selan L., Artini M.**  
Essential oils against bacterial isolates from cystic fibrosis patients by means of antimicrobial and unsupervised machine learning approaches  
*Scientific Reports* 2020; 10: 1:2653
- Romano MT., Premraj S., Bray JM., Murillo LC.**  
Ceftolozane/tazobactam for pulmonary exacerbation in a 63-year-old cystic fibrosis patient with renal insufficiency and an elevated MIC to *Pseudomonas aeruginosa*  
*IDCases* 2020; 21: ArtNo: e00830
- Rosenfeld M., Rayner O., Smyth AR.**  
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2020; : 9:CD001912
- Rouillard KR., Markovetz MR., Bacudio LG., Hill DB., Schoenfisch MH.**  
*Pseudomonas aeruginosa* Biofilm Eradication via Nitric Oxide-Releasing Cyclodextrins  
*ACS Infectious Diseases* 2020; 6: 1940 - 1950
- Silva E., Monteiro R., Grainha T., Alves D., Pereira MO., Sousa AM.**  
Fostering Innovation in the Treatment of Chronic Polymicrobial Cystic Fibrosis-Associated Infections Exploring Aspartic Acid and Succinic Acid as Ciprofloxacin Adjuvants  
*Frontiers in Cellular and Infection Microbiology* 2020; 10: ArtNo: 441
- Sorensen M., Khakimov B., Nurjadi D., Boutin S., Yi BQ., Dalpke AH., Eigenbrod T.**  
Comparative evaluation of the effect of different growth media on in vitro sensitivity to azithromycin in multi-drug resistant *Pseudomonas aeruginosa* isolated from cystic fibrosis patients  
*Antimicrobial Resistance and Infection Control* 2020; 9: 1:197

**Stokniene J., Powell LC., Aarstad OA., Aachmann FL., Rye PD., Hill KE., Thomas DW., Ferguson EL.**

Bi-Functional Alginate Oligosaccharide-Polymyxin Conjugates for Improved Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections  
*Pharmaceutics* 2020; 12: 11:1080

**Svoboda E.**

Bacteria-eating viruses could provide a route to stability in cystic fibrosis  
*Nature* 2020; 583: S8 - S9

**Sweeney E., Sabnis A., Edwards AM., Harrison F.**

Effect of host-mimicking medium and biofilm growth on the ability of colistin to kill *Pseudomonas aeruginosa*  
*Microbiology* 2020; 166: 1171 - 1180

**Tan M., Reyes-Ortega F., Schneider-Futschik EK.**

Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis  
*Magnetochemistry* 2020; : 8:CD010810

**Trespidi G., Scoffone VC., Barbieri G., Riccardi G., De Rossi E., Buroni S.**

Molecular Characterization of the Burkholderia cenocepacia cdx Operon and FtsZ Interactors as New Targets for Novel Antimicrobial Design  
*Antibiotics-Basel* 2020; 9: 12:841

**Valinetz E., Karita HS., Pottinger PS., Jain R.**

Novel Administration of Clofazimine for the Treatment of Mycobacterium avium Infection  
*Open Forum Infectious Diseases* 2020; 7: 6:ofaa183

**van Koningsbruggen-Rietschel S., Davies JC., Pressler T., Fischer R., MacGregor G., Donaldson SH., Smerud K., Meland N., Mortensen J., Fosbol MO., Downey DG., Myrset AH., Flaten H., Rye PD.**

Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study  
*ERJ Open Research* 2020; 6: 4:00132-2020

**Varela MC., Roch M., Taglialegna A., Long SW., Saavedra MO., Rose WE., Davis JJ., Hoffman LR., Hernandez RE., Rosato RR., Rosato AE.**

Carbapenems drive the collateral resistance to ceftaroline in cystic fibrosis patients with MRSA  
*Communications Biology* 2020; 3: 1:599

**Yusuf E., van Westreenen M., Goessens W., Croughs P.**

The accuracy of four commercial broth microdilution tests in the determination of the minimum inhibitory concentration of colistin  
*Annals of Clinical Microbiology and Antimicrobials* 2020; 19: 1:42

## Cardiology

**Scott JA., Barry PJ., Jones AM., Athwal VS.**

Management of superior mesenteric venous thrombus in cystic fibrosis related liver disease  
*Paediatric Respiratory Reviews* 2020; 35: 106 - 108

## Cell Biology

**Abreu SC., Hampton TH., Hoffman E., Dearborn J., Ashare A., Sidhu KS., Matthews DE., McKenna DH., Amiel E., Barua J., Krasnodembskaya A., English K., Mahon B., Dos Santos C., Cruz FF., Chambers DC., Liu KD., Matthay MA., Cramer RA.**

Differential effects of the cystic fibrosis lung inflammatory environment on mesenchymal stromal cells  
*American Journal of Physiology-Lung Cellular and Molecular Physiology* 2020; 319: L908 - L925

**Bertelsen A., Elborn SJ., Schock BC., Omri A., Omri A.**

Toll like Receptor signalling by *Prevotella histicola* activates alternative NF-kappa B signalling in Cystic Fibrosis bronchial epithelial cells compared to *P. aeruginosa*  
*PLoS One* 2020; 15: 10:e0235803

**Bratcher PE., Yadav S., Shaughnessy CA., Thornell IM., Zeitlin PL.**

Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings  
*Physiological Reports* 2020; 8: 19:e14603

**Centko RM., Carlile GW., Barne I., Patrick BO., Blagojevic P., Thomas DY., Andersen RJ.**

Combination of Selective PARP3 and PARP16 Inhibitory Analogues of Latonduine A Corrects F508del-CFTR Trafficking  
*ACS Omega* 2020; 5: 25593 - 25604

**De Palma FDE., Raia V., Kroemer G., Maiuri MC.**

The Multifaceted Roles of MicroRNAs in Cystic Fibrosis  
*Diagnostics* 2020; 10: 12:1102

**Dhooghe B., Bouzin C., Mottais A., Hermans E., Delion M., Panin N., Noel S., Leal T.**

Vardenafil increases intracellular accumulation of the most prevalent mutant cystic fibrosis transmembrane conductance regulator (CFTR) in human bronchial epithelial cells  
*Biology Open* 2020; 9: 8:bio053116

**Fabbi E., Tamanini A., Jakova T., Gasparello J., Manicardi A., Corradini R., Finotti A., Borgatti M., Lampronti I., Munari S., Dececchi MC., Cabrini G., Gambari R.**

Treatment of human airway epithelial Calu-3 cells with a peptide-nucleic acid (PNA) targeting the microRNA miR-101-3p is associated with increased expression of the cystic fibrosis Transmembrane Conductance Regulator gene  
*European Journal of Medicinal Chemistry* 2021; 209: ArtNo: 112876

**Fiore M., Garcia-Valverde M., Carreira-Barral I., Moran O.**

The different anion transport capability of prodiginine- and tambjamine-like molecules  
*European Journal of Pharmacology* 2020; 889: ArtNo: 173592

**Hewson CK., Capraro A., Wong SL., Pandzic E., Zhong L., Fernando BSM., Awatade NT., Hart-Smith G., Whan RM., Thomas SR., Jaffe A., Bridge WJ., Waters SA.**

Novel Antioxidant Therapy with the Immediate Precursor to Glutathione, gamma-Glutamylcysteine (GGC), Ameliorates LPS-Induced Cellular Stress in In Vitro 3D-Differentiated Airway Model from Primary Cystic Fibrosis Human Bronchial Cells  
*Antioxidants* 2020; 9: 12:1204

**Hodos RA., Strub MD., Ramachandran S., Li L., McCray PB., Dudley JT.**

Integrative genomic meta-analysis reveals novel molecular insights into cystic fibrosis and Delta F508-CFTR rescue  
*Scientific Reports* 2020; 10: 1:20553

**Horn T., Ludwig M., Eickmeier O., Neerinx AH., van der Zee AMH., Smaczny C., Wagner TOF., Schubert R., Zielen S., Majoor C., Bos LD., Schmitt-Grohe S.**

Impact of a Gap Junction Protein Alpha 4 Variant on Clinical Disease Phenotype in F508del Homozygous Patients With Cystic Fibrosis  
*Frontiers in Genetics* 2020; 11: 1:448

**Khatibi S., Modaresi M., Oskuee RK., Salehi M., Aghae-Bakhtiari SH.**

Genetic modification of cystic fibrosis with Delta F508 mutation of CFTR gene using the CRISPR system in peripheral blood mononuclear cells  
*Iranian Journal of Basic Medical Sciences* 2021; 24: 73 - 78

**Kolonko AK., Efing J., Gonzalez-Espinosa Y., Bangel-Ruland N., van Driessche W., Goycoolea FM., Weber WM.**

Capsaicin-Loaded Chitosan Nanocapsules for wtCFTR-mRNA Delivery to a Cystic Fibrosis Cell Line  
*Biomedicine* 2020; 8: 9:364

**Kondrateva E., Adilgereeva E., Amelina E., Tabakov V., Demchenko A., Ustinov K., Yasinovsky M., Voronina E., Lavrov A., Smirnikhina S.**

Generation of induced pluripotent stem cell line (RCMGi001-A) from human skin fibroblasts of a cystic fibrosis patient with p.F508del mutation  
*Stem Cell Research* 2020; 48: ArtNo: 101933

- Lavi E., Gileles-Hillel A., Zangen D.**  
Somatic growth in cystic fibrosis  
*Current Opinion in Endocrinology Diabetes and Obesity* 2020; 27: 38 - 46
- Lee AJ., Einarsson GG., Gilpin DF., Tunney MM.**  
Multi-Omics Approaches: The Key to Improving Respiratory Health in People With Cystic Fibrosis?  
*Frontiers in Pharmacology* 2020; 11: ArtNo: 569821
- Lee RE., Miller SM., Mascenik TM., Lewis CA., Dang H., Boggs ZH., Tarran R., Randell SH.**  
Assessing Human Airway Epithelial Progenitor Cells for Cystic Fibrosis Cell Therapy  
*American Journal of Respiratory Cell and Molecular Biology* 2020; 63: 374 - 385
- Leiter H., Toepfer S., Messner P., Rabensteiner M., Gostner JM., Lackner M., Hermann M., Nagl M.**  
Microbicidal activity of N-chlorotaurine can be enhanced in the presence of lung epithelial cells  
*Journal of Cystic Fibrosis* 2020; 19: 1011 - 1017
- Luscher A., Simonin J., Falconnet L., Valot B., Hocquet D., Chanson M., Resch G., Kohler T., van Delden C.**  
Combined Bacteriophage and Antibiotic Treatment Prevents *Pseudomonas aeruginosa* Infection of Wild Type and CFTR Epithelial Cells  
*Frontiers in Microbiology* 2020; 11: ArtNo: 1947
- Mukherjee A., MacDonald KD., Kim J., Henderson MI., Eygeris Y., Sahay G.**  
Engineered mutant alpha-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis-based cell and mice models  
*Science Advances* 2020; 6: 47:eabc5911
- Pibiri I., Melfi R., Tutone M., Di Leonardo A., Pace A., Lentini L.**  
Targeting Nonsense: Optimization of 1,2,4-Oxadiazole TRIDs to Rescue CFTR Expression and Functionality in Cystic Fibrosis Cell Model Systems  
*International Journal of Molecular Sciences* 2020; 21: 17:6420
- Prins S., Langron E., Hastings C., Hill EJ., Stefan AC., Griffin LD., Vergani P.**  
Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity  
*Journal of Biological Chemistry* 2020; 295: 16529 - 16544
- Rayner RE., Wellmerling J., Osman W., Honesty S., Alfaro M., Peoples ME., Cormet-Boyaka E.**  
In vitro 3D culture lung model from expanded primary cystic fibrosis human airway cells  
*Journal of Cystic Fibrosis* 2020; 19: 752 - 761
- Saint-Criq V., Delpiano L., Casement J., Onuora JC., Lin JH., Gray MA.**  
Choice of Differentiation Media Significantly Impacts Cell Lineage and Response to CFTR Modulators in Fully Differentiated Primary Cultures of Cystic Fibrosis Human Airway Epithelial Cells  
*Cells* 2020; 9: 9:2137
- Sainz-Ramos M., Villate-Beitia I., Gallego I., Qtaish NAL., Lopez-Mendez TB., Eritja R., Grijalvo S., Puras G., Pedraz JL.**  
Non-viral mediated gene therapy in human cystic fibrosis airway epithelial cells recovers chloride channel functionality  
*International Journal of Pharmaceutics* 2020; 588: ArtNo: 119757
- Sheikh Z., Bradbury P., Pozzoli M., Young PM., Ong HX., Traini D.**  
An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line  
*European Journal of Pharmaceutics and Biopharmaceutics* 2020; 156: 121 - 130
- Shibata S., Ajiro M., Hagiwara M.**  
Mechanism-Based Personalized Medicine for Cystic Fibrosis by Suppressing Pseudo Exon Inclusion  
*Cell Chemical Biology* 2020; 27: 1472 - +
- Smirnikhina SA., Kondrateva EV., Adilgereeva EP., Anuchina AA., Zaynitdinova MI., Slesarenko YS., Ershova AS., Ustinov KD., Yasinovsky MI., Amelina EL., Voronina ES., Yakushina VD., Tabakov VY., Lavrov AV.**  
P.F508del editing in cells from cystic fibrosis patients  
*PLoS One* 2020; 15: 11:e0242094
- Sousa L., Pankonien I., Simoes FB., Chanson M., Amaral MD.**  
Impact of KLF4 on Cell Proliferation and Epithelial Differentiation in the Context of Cystic Fibrosis  
*International Journal of Molecular Sciences* 2020; 21: 18:6717
- Wei T., Sui HS., Su YP., Cheng WJ., Liu YH., He ZL., Ji QC., Xu CL.**  
Research advances in molecular mechanisms underlying the pathogenesis of cystic fibrosis: From technical improvement to clinical applications  
*Molecular Medicine Reports* 2020; 22: 4992 - 5002
- Xie YL., Lu L., Tang XX., Moninger TO., Huang TJ., Stoltz DA., Welsh MJ.**  
Acidic Submucosal Gland pH and Elevated Protein Concentration Produce Abnormal Cystic Fibrosis Mucus  
*Developmental Cell* 2020; 54: 488
- Zhu XJ., Zhang WT., Jin LL., Zhang GP., Yang H., Yu B.**  
Inhibitory activities of curzerenone, curdione, furanodienone, curcumol and germacrone on Ca<sup>2+</sup>-activated chloride channels  
*Fitoterapia* 2020; 147: ArtNo: 104736
- ## CFTR
- Akrimajirachoote N., Satitsri S., Sommart U., Rukachaisirikul V., Muanprasat C.**  
Inhibition of CFTR-mediated intestinal chloride secretion by a fungus-derived arthropollide A: Mechanism of action and anti-diarrheal efficacy  
*European Journal of Pharmacology* 2020; 885: ArtNo: 173393
- Amaral MD.**  
How to determine the mechanism of action of CFTR modulator compounds: A gateway to theranostics  
*European Journal of Medicinal Chemistry* 2021; 210: ArtNo: 112989
- Boussarrou A., Audrezet MP., Raynal C., Sermet-Gaudelus I., Bienvenu T., Ferec C., Bergougnoux A., Lopez M., Scotet V., Munck A., Girodon E.**  
Penetrance is a critical parameter for assessing the disease liability of CFTR variants  
*Journal of Cystic Fibrosis* 2020; 19: 949 - 954
- Brindani N., Gianotti A., Giovanni S., Giacomina F., Di Fruscina P., Sorana F., Bertozzi SM., Ottonello G., Goldoni L., Penna I., Russo D., Summa M., Bertorelli R., Ferrera L., Pesce E., Sondo E., Galletta LJV., Bandiera T., Pedemonte**  
Identification, Structure-Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1H-pyrido[4,3-b]indoles as a Novel Class of CFTR Potentiators  
*Journal of Medicinal Chemistry* 2020; 63: 11169 - 11194
- Briottet M., Shum M., Urbach V.**  
The Role of Specialized Pro-Resolving Mediators in Cystic Fibrosis Airways Disease  
*Frontiers in Pharmacology* 2020; 11: ArtNo: 1290
- Chen HQ., Chen WL., Yao YL., Ye NB., Hou N., Luo JD.**  
Upregulation of CFTR Protects against Palmitate-Induced Endothelial Dysfunction by Enhancing Autophagic Flux  
*Oxidative Medicine and Cellular Longevity* 2020; 2020: ArtNo: 8345246
- Choi SH., Reeves RE., Ibarra GSR., Lynch TJ., Shahin WS., Feng ZH., Gasser GN., Winter MC., Evans TIA., Liu XM., Luo MH., Zhang YL., Stoltz DA., Devor EJ., Yan ZY., Engelhardt JF.**  
Detargeting Lentiviral-Mediated CFTR Expression in Airway Basal Cells Using miR-106b  
*Genes* 2020; 11: 10:1169

- Cuevas-Ocana S., Laselva O., Avolio J., Nenna R.**  
The era of CFTR modulators: improvements made and remaining challenges  
*Breathe* 2020; 16: 2:200016
- Cui XR., Wu XQ., Li Q., Jing X.**  
Mutations of the cystic fibrosis transmembrane conductance regulator gene in males with congenital bilateral absence of the vas deferens: Reproductive implications and genetic counseling  
*Molecular Medicine Reports* 2020; 22: 3587 - 3596
- Dagenais RVE., Su VCC., Quon BS.**  
Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review  
*Journal of Clinical Medicine* 2021; 10: 1:23
- Di Fulvio M., Bogdani M., Velasco M., McMillen TS., Ridaura C., Kelly L., Almutairi MM., Kursan S., Sajib A., Hiriart M., Aguilar-Bryan L.**  
Heterogeneous expression of CFTR in insulin-secreting beta-cells of the normal human islet  
*PLoS One* 2020; 15: 12:e0242749
- Dukovski D., Vilella A., Bastos C., King R., Finley D., Kelly JW., Morimoto RL., Hartl FU., Munoz B., Lee PS., Zecevic M., Miller JP.**  
Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA  
*Journal of Cystic Fibrosis* 2020; 19: 733 - 741
- Espósito MV., Aveta A., Comegna M., Cerneria G., Iacotucci P., Carnovale V., Taccetti G., Terlizzi V., Castaldo G.**  
Extensive CFTR Gene Analysis Revealed a Higher Occurrence of Cystic Fibrosis Transmembrane Regulator-Related Disorders (CFTR-RD) among CF Carriers  
*Journal of Clinical Medicine* 2020; 9: 12:3853
- Ghelani DP., Schneider-Futschik EK.**  
Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation  
*ACS Pharmacology & Translational Science* 2020; 3: 4 - 10
- Havermans T., Duff AJA.**  
Changing landscape: psychological care in the era of cystic fibrosis transmembrane conductance regulator modulators  
*Current Opinion in Pulmonary Medicine* 2020; 26: 696 - 701
- Heda GD., Shrestha L., Thapa S., Ghimire S., Raut D.**  
Optimization of western blotting for the detection of proteins of different molecular weight  
*Biotechniques* 2020; 68: 319
- Huang J., Lam H., Koziol-White C., Limjunyawong N., Kim D., Kim N., Karmacharya N., Rajkumar P., Firer D., Dalesio NM., Jude J., Kurten RC., Pluznick JL., Deshpande DA., Penn RB., Liggett SB., Panettieri RA., Dong XZ., An SS.**  
The odorant receptor OR2W3 on airway smooth muscle evokes bronchodilation via a cooperative chemosensory tradeoff between TMEM16A and CFTR  
*Proceedings of the National Academy of Sciences of the United States* 2020; 117: 28485 - 28495
- Jiang X., Shao YQ., Araj FG., Amin AA., Greenberg BM., Drazner MH., Xing C., Mammen PPA.**  
Heterozygous Cystic Fibrosis Transmembrane Regulator Gene Missense Variants Are Associated With Worse Cardiac Function in Patients With Duchenne Muscular Dystrophy  
*Journal of the American Heart Association* 2020; 9: 19:e016799
- Laselva O., Eckford PDW., Bartlett C., Ouyang H., Gunawardena TNA., Gonska T., Moraes TJ., Bear CE.**  
Functional rescue of c.3846G > A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action  
*Journal of Cystic Fibrosis* 2020; 19: 717 - 727
- Leir SH., Yin SY., Kerschner JL., Cosme W., Harris A.**  
An atlas of human proximal epididymis reveals cell-specific functions and distinct roles for CFTR  
*Life Science Alliance* 2020; 3: 11:e202000744
- Lidington D., Bolz SS.**  
A Scientific Rationale for Using Cystic Fibrosis Transmembrane Conductance Regulator Therapeutics in COVID-19 Patients  
*Frontiers in Physiology* 2020; 11: ArtNo: 583862
- Liu YY., Lin ZY., Liu MF., Liao HJ., Chen Y., Zhang XH., Chan HC., Zhou B., Rao L., Sun HQ.**  
CFTR deficiency causes cardiac dysplasia during zebrafish embryogenesis and is associated with dilated cardiomyopathy  
*Mechanisms of Development* 2020; 163: ArtNo: 103627
- Liu YY., Lin ZY., Sun HQ.**  
Cystic fibrosis transmembrane conductance regulator (CFTR) regulates embryonic organizer formation during zebrafish early embryogenesis  
*International Journal of Developmental Biology* 2020; 64: 409 - 413
- Lopes-Pacheco M., Silva IAL., Turner MJ., Carlile GW., Sondo E., Thomas DY., Pedemonte N., Hanrahan JW., Amaral MD.**  
Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR  
*Biochemical Pharmacology* 2020; 180: ArtNo: 114133
- Loureiro CA., Pinto FR., Barros P., Matos P., Jordan P.**  
A SYK/SHC1 pathway regulates the amount of CFTR in the plasma membrane  
*Cellular and Molecular Life Sciences* 2020; 77: 4997 - 5015
- Luo SG., Feng JR., Zhang YN., Yang XJ., Ma GC., Hu TF., Xi Y., Tu XC., Wang CL., Zhang H., Zou ZJ., Zhang Y.**  
Mutation analysis of the cystic fibrosis transmembrane conductance regulator gene in Chinese congenital absence of vas deferens patients  
*Gene* 2021; 765: ArtNo: 145045
- Michaels WE., Bridges RJ., Hastings ML.**  
Antisense oligonucleotide-mediated correction of CFTR splicing improves chloride secretion in cystic fibrosis patient-derived bronchial epithelial cells  
*Nucleic Acids Research* 2020; 48: 7454 - 7467
- Mihalyi C., Jordanov I., Torocsik B., Csanady L.**  
Simple binding of protein kinase A prior to phosphorylation allows CFTR anion channels to be opened by nucleotides  
*Proceedings of the National Academy of Sciences of the United States* 2020; 117: 21740 - 21746
- Park JK., Shrivastava A., Zhang CK., Pollok BA., Finkbeiner WE., Gibb ER., Ly NP., Illek B.**  
Functional Profiling of CFTR-Directed Therapeutics Using Pediatric Patient-Derived Nasal Epithelial Cell Models  
*Frontiers in Pediatrics* 2020; 8: ArtNo: 536
- Parodi A., Righetti G., Pesce E., Salis A., Tasso B., Urbinati C., Tomati V., Damonte G., Rusnati M., Pedemonte N., Cichero E., Millo E.**  
Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays  
*European Journal of Medicinal Chemistry* 2020; 208: ArtNo: 112833
- Prins S., Langron E., Hastings C., Hill EJ., Stefan AC., Griffin LD., Vergani P.**  
Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity  
*Journal of Biological Chemistry* 2020; 295: 16529 - 16544
- Quaresma MC., Pankonien I., Clarke LA., Sousa LS., Silva IAL., Railean V., Dousova T., Fuxe J., Amaral MD.**  
Mutant CFTR Drives TWIST1 mediated epithelial-mesenchymal transition  
*Cell Death & Disease* 2020; 11: 10:920
- Raynal C., Corvol H.**  
Variant classifications, databases and genotype-phenotype correlations  
*Archives de Pediatrie* 2020; 27:

**Righetti G., Casale M., Liessi N., Tasso B., Salis A., Tonelli M., Millo E., Pedemonte N., Fossa P., Cichero E.**  
Molecular Docking and QSAR Studies as Computational Tools Exploring the Rescue Ability of F508del CFTR Correctors  
*International Journal of Molecular Sciences* 2020; 21: 21:8084

**Righetti G., Casale M., Tonelli M., Liessi N., Fossa P., Pedemonte N., Millo E., Cichero E.**  
New Insights into the Binding Features of F508del CFTR Potentiators: A Molecular Docking, Pharmacophore Mapping and QSAR Analysis Approach  
*Pharmaceuticals* 2020; 13: 12:445

**Scudieri P., Musante I., Venturini A., Guidone D., Genovese M., Cresta F., Caci E., Palleschi A., Poeta M., Santamaria F., Ciciriello F., Lucidi V., Galietta LJV.**  
Ionocytes and CFTR Chloride Channel Expression in Normal and Cystic Fibrosis Nasal and Bronchial Epithelial Cells  
*Cells* 2020; 9: 9:2090

**Shishido H., Yoon JS., Yang ZY., Skach WR.**  
CFTR trafficking mutations disrupt cotranslational protein folding by targeting biosynthetic intermediates  
*Nature Communications* 2020; 11: 1:4258

**Son JH., Phuan PW., Zhu JS., Lipman E., Cheung A., Tsui KY., Tantillo DJ., Verkman AS., Haggie PM., Kurth MJ.**  
1-BENZYLSPIRO[PIPERIDINE-4,1'-PYRIDO[3,4-b]indole] 'co-potentiators' for minimal function CFTR mutants  
*European Journal of Medicinal Chemistry* 2021; 209: ArtNo: 112888

**Spano V., Venturini A., Genovese M., Barreca M., Raimondi MV., Montalbano A., Galietta LJV., Barraja P.**  
Current development of CFTR potentiators in the last decade  
*European Journal of Medicinal Chemistry* 2020; 204: ArtNo: 112631

**Veit G., Roldan A., Hancock MA., Da Fonte DF., Xu HJ., Hussein M., Frenkiel S., Matouk E., Velkov T., Lukacs GL.**  
Allosteric folding correction of F508del and rare CFTR mutants by elxacaftor-tezacaftor-ivacaftor (Trikafta) combination  
*JCI Insight* 2020; 5: 18:e139983

**Wang W., Fu LW., Liu ZY., Wen H., Rab A., Hong JS., Kirk KL., Rowe SM.**  
G551D mutation impairs PKA-dependent activation of CFTR channel that can be restored by novel GOF mutations  
*American Journal of Physiology-lung Cellular and Molecular Physiology* 2020; 319: L770 - L785

## Clinical

**Agarwal N., Apperley L., Taylor NF., Taylor DR., Ghataore L., Rumsby E., Treslove C., Holt R., Thursfield R., Senniappan S.**  
Posaconazole-Induced Hypertension Masquerading as Congenital Adrenal Hyperplasia in a Child with Cystic Fibrosis  
*Case Reports in Medicine* 2020; 2020: ArtNo: 8153012

**Amaral MB., Rego S.**  
Rare diseases on the agenda for innovation in health: progress and challenges with cystic fibrosis  
*Cadernos de Saude Publica* 2020; 36: 12:e00115720

**Balfour-Lynn IM., Khan K., Pentayya N., Pheasant C., Bentley S., Makhecha S.**  
Initiating Self-Administration of Medicines for in patients with cystic fibrosis  
*Archives of Disease in Childhood* 2020; 105: 986 - 990

**Blin T., Flament T., Mankikian J., Vibet S., Chaumier F.**  
Palliative care in cystic fibrosis  
*BMJ Supportive & Palliative Care* 2020; 10: 341 - 342

**Buse C., Brown N., Nettleton S., Martin D., Lewis A.**  
Caring through distancing: Spatial boundaries and proximities in the cystic fibrosis clinic  
*Social Science & Medicine* 2020; 265: ArtNo: 113531

**Cao YM., Donaldson R., Lee D.**  
"Summer hypokalemia" as an initial presentation of cystic fibrosis in a morbidly obese African American adult: case report  
*BMC Nephrology* 2020; 21: 1:462

**Coffey N., O'Leary F., Burke F., Roberts A., Hayes M.**  
Periodontal and oral health status of people with Cystic Fibrosis: a systematic review  
*Journal of Dentistry* 2020; 103: ArtNo: 103509

**Ghimire S., Yerneni H., Oyadomari TA., Sedlacek M.**  
Metabolic Alkalosis and Cystic Fibrosis: A Case Report  
*Annals of Internal Medicine* 2020; 173:

**Hjelm M., Shaikhkhalil AK.**  
Celiac Disease in Patients With Cystic Fibrosis on Ivacaftor: A Case Series  
*Journal of Pediatric Gastroenterology and Nutrition* 2020; 71: 257 - 260

**Holman B., DeVito NJ., Vassar M.**  
Transparency and diversity in cystic fibrosis research  
*Lancet* 2020; 396: 601 - 602

**Kapnadak SG., Ramos KJ., Dellon EP.**  
Enhancing care for individuals with advanced cystic fibrosis lung disease  
*Pediatric Pulmonology* 2021; 56:

**Keivanfar M., Daris S., Reisi M., Mehrkesh M.**  
The fractional excretion of sodium in patients with cystic fibrosis treated with oral sodium chloride  
*American Journal of Clinical and Experimental Urology* 2020; 8: 185 - 190

**Mayer-Hamblett N., VanDevanter DR.**  
Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis  
*Trends in Molecular Medicine* 2020; 26: 1068 - 1077

**McCoy KS., Heijerman H., Taylor-Cousar JL., Waltz D., Sosnay PR., Ramsey BW., Rowe S., Welter J.**  
Transparency and diversity in cystic fibrosis research reply  
*Lancet* 2020; 396: 602

**McGarry M.**  
Transparency and diversity in cystic fibrosis research  
*Lancet* 2020; 396: 601

**Mooney C., McKiernan PJ., Raoof R., Henshall DC., Linnane B., McNally P., Glasgow AMA., Greene CM.**  
Plasma microRNA levels in male and female children with cystic fibrosis  
*Scientific Reports* 2020; 10: 1:1141

**Oates GR., Baker E., Rowe SM., Gutierrez HH., Schechter MS., Morgan W., Harris WT.**  
Tobacco smoke exposure and socioeconomic factors are independent predictors of pulmonary decline in pediatric cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 783 - 790

**Patel V., Majumdar T., Samreen I., Grewal H., Kaleekal T.**  
Primary lung carcinoma in cystic fibrosis: A case report and literature review  
*Respiratory Medicine Case Reports* 2020; 31: ArtNo: 101242

**Pesci E., Pedemonte N., Leoni A., Locatelli A., Morigi R.**  
Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis  
*Bioorganic & Medicinal Chemistry Letters* 2020; 30: 21:127473

**Poulimeneas D., Grammatikopoulou MG., Petrocheilou A., Kaditis AG., Vassilakou T.**  
Triage for Malnutrition Risk among Pediatric and Adolescent Outpatients with Cystic Fibrosis, Using a Disease-Specific Tool  
*Children-basel* 2020; 7: 12:269

**Rachel M., Topolewicz S., Sliwczynski A., Galiniak S.**  
Managing Cystic Fibrosis in Polish Healthcare  
*International Journal of Environmental Research and Public Health* 2020; 17: 20:7630

**Rahim FHA., Thambiah SC., Samsudin IN., Mokhtar NM.**  
The role of biochemical testing in cystic fibrosis  
*Malaysian Journal of Pathology* 2020; 42: 297 - 300

**Roughley M., MacDougall L., Erolin C.**  
Cystic Fibrosis: A Pocket Guide  
*Journal of Visual Communication in Medicine* 2020; 43: 198 - 210

**Shakkottai A., Nasr SZ., Hassan F., Irani S., O'Brien LM., Chervin RD.**

Sleep-disordered breathing in cystic fibrosis  
*Sleep Medicine* 2020; 74: 57 - 65

**Smith MA., McGarry ME., Ly NP., Zinter MS.**  
Outcomes of Children With Cystic Fibrosis Admitted to PICUs\*  
*Pediatric Critical Care Medicine* 2020; 21: E879 - E887

**Thornton T., Pillai A.**  
Encephalopathy in cystic fibrosis  
*Paediatric Respiratory Reviews* 2020; 35: 93 - 94

**Tindell W., Su A., Oros SM., Rayapati AO., Rakesh G.**  
Trikafta and Psychopathology in Cystic Fibrosis: A Case Report  
*Psychosomatics* 2020; 61: 735 - 738

**Waters I.**  
Specialist Services Committee backs expansive strategy for improving cystic fibrosis patient care  
*British Columbia Medical Journal* 2020; 62: 347

**Wisniewski BL., Shrestha CL., Zhang SZ., Thompson R., Gross M., Groner JA., Uppal K., Ramilo O., Mejias A., Kopp BT.**  
Metabolomics profiling of tobacco exposure in children with cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 791 - 800

**Womack C., Farsin R., Farsad M., Chaudary N.**  
Emerging Alternatives to Conventional Clinic Visits in the Era of COVID-19: Adoption of Telehealth at VCU Adult Cystic Fibrosis Center  
*International Journal of General Medicine* 2020; 13: 162 - 175

**Ziyae F., Dehghani SM., Hosseini S., Zohalinezhad ME., Aleyasin S., Javaherizadeh H.**  
Clinical manifestation, laboratory findings, and outcome of children with cystic fibrosis over a 10-year period in South Iran  
*Egyptian Pediatric Association Gazette* 2020; 68: 1:33

## Databases & Registries

**Earnest A., Salimi F., Wainwright CE., Bell SC., Ruseckaite R., Ranger T., Kotsimbos T., Ahern S.**  
Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry  
*Scientific Reports* 2020; 10: 1:17421

**Ratnayake I., Ahern S., Ruseckaite R.**  
A systematic review of patient-reported outcome measures (PROMs) in cystic fibrosis  
*BMJ Open* 2020; 10: 10:e033867

## Diabetes

**Colomba J., Rabasa-Lhoret R., Bonhoure A., Bergeron C., Boudreau V., Tremblay F., Senior P., Potter K.**  
Dyslipidemia is not associated with the development of glucose intolerance or diabetes in cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 704 - 711

**Karpova EV., Karyakin AA.**  
Noninvasive monitoring of diabetes and hypoxia by wearable flow-through biosensors  
*Current Opinion in Electrochemistry* 2020; 23: 16 - 20

**Kempegowda P., Sunsoa H., Chandan JS., Quinn LM., Amrelia PM., Atta SN., Amir S., Teh YS., Chaudhry S., de Bray A., Rashid R., Whitehouse JL., Nash EF., Syed A.**  
Retinopathy and microalbuminuria are common microvascular complications in cystic fibrosis-related diabetes  
*Therapeutic Advances in Endocrinology and Metabolism* 2020; 11: ArtNo: 2042018

**Kilberg MJ., Harris C., Sheikh S., Stefanovski D., Cuchel M., Kubrak C., Hadjiliadis D., Rubenstein RC., Rickels MR., Kelly A.**  
Hypoglycemia and Islet Dysfunction Following Oral Glucose Tolerance Testing in Pancreatic-Insufficient Cystic Fibrosis  
*Journal of Clinical Endocrinology & Metabolism* 2020; 105: 10:dga448

**Onady GM., Stolfi A.**  
Drug treatments for managing cystic fibrosis-related diabetes  
*Cochrane Database of Systematic Reviews* 2020; : 10:CD004730

**Prentice BJ., Ooi CY., Verge CF., Hameed S., Widger J.**  
Glucose abnormalities detected by continuous glucose monitoring are common in young children with Cystic Fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 700 - 703

**Salzano G., Passanisi S., Lucanto MC., Costa S., Pajno GB., Lombardo F.**  
GCK-MODY in a child with cystic fibrosis: the doubt of the treatment plan  
*Journal of Pediatric Endocrinology & Metabolism* 2020; 33: 1359 - 1362

**Sheikh S., Localio AR., Kelly A., Rubenstein RC.**  
Abnormal glucose tolerance and the 50-gram glucose challenge test in Cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 696 - 699

**Stonestreet J., Ar A., Herd K., Matson A., Bell J.**  
Carbohydrate counting accuracy in adults with cystic fibrosis related diabetes  
*Nutrition & Dietetics* 2020; 77: 508 - 514

## Diagnosis

**Benabdelkamel H., Alamri H., Okla M., Masood A., Jabar MA., Alanazi IO., Alfadda AA., Nizami I., Dasouki M., Rahman AMA.**  
Serum-Based Proteomics Profiling in Adult Patients with Cystic Fibrosis  
*International Journal of Molecular Sciences* 2020; 21: 19:7415

**Bienvenu T., Nguyen-Khoa T.**  
Current and future diagnosis of cystic fibrosis: Performance and limitations  
*Archives de Pediatrie* 2020; 27:

**Bryon M.**  
Breaking the diagnosis of cystic fibrosis to parents: A process not a one-off event  
*Paediatric Respiratory Reviews* 2020; 35: 103 - 105

**Desai S., Lam GY., Sykes J., Stephenson AL., Quon BS.**  
Eligibility of CFTR modulators for the adult-diagnosed cystic fibrosis population  
*Journal of Cystic Fibrosis* 2020; 19: 840 - 841

**Hauke A., Oertel S., Knoke L., Fein V., Maier C., Brinkmann F., Jank MPM.**  
Screen-Printed Sensor for Low-Cost Chloride Analysis in Sweat for Rapid Diagnosis and Monitoring of Cystic Fibrosis  
*Biosensors-Basel* 2020; 10: 9:123

**Minso R., Schulz A., Dopfer C., Alfeis N., van Barneveld A., Makartian-Gyulumyan L., Hansen G., Junge S., Muller C., Ringshausen FCC., Sauer-Heilborn A., Stanke F., Stolpe C., Tamm S., Welte T., Dittrich AM., Tummeler B.**  
Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive CFTR genetics and sweat test  
*BMJ Open Respiratory Research* 2020; 7: 1:e000736

**Pagin A., Sermet-Gaudelus I., Burgel PR.**  
Genetic diagnosis in practice: From cystic fibrosis to CFTR-related disorders  
*Archives de Pediatrie* 2020; 27:

**Sagesse GJ., Yadava S., Mandava A.**  
Atypical Cystic Fibrosis: Diagnosis at the Age of 57 Years  
*Cureus* 2020; 12: 10:e10863

**Silva IAL., Duarte A., Marson FAL., Centeio R., Dousova T., Kunzelmann K., Amaral MD.**  
Assessment of Distinct Electrophysiological Parameters in Rectal Biopsies for the Choice of the Best Diagnosis/Prognosis Biomarkers for Cystic Fibrosis  
*Frontiers in Physiology* 2020; 11: ArtNo: 604580

## Epidemiology

**Dayangac-Erden D., Atalay M., Emiralioğlu N., Hizal M., Polat S., Ozelik U., Yalcin E., Dogru D., Yilmaz E., Kiper N.**  
Mutations of the CFTR gene and novel variants in Turkish patients with cystic fibrosis: 24-years experience  
*Clinica Chimica Acta* 2020; 510: 252 - 259

**Kiseleva A., Klimushina M., Sotnikova E., Skirko O., Divashuk M., Kurilova O., Ershova A., Khlebus E., Zharikova A., Efimova I., Pokrovskaya M., Slominsky PA., Shalnova S., Meshkov A., Drapkina O.**  
Cystic Fibrosis Polymorphic Variants in a Russian Population  
*Pharmacogenomics & Personalized Medicine* ; :

## Exercise

**Aspinall SP., Hill DM., Mackintosh KA., McNarry MA.**  
Reduced exertion high-intensity interval training (REHIT) in an adult with Cystic Fibrosis: A mixed-methods case study  
*Respiratory Medicine Case Reports* 2020; 31: ArtNo: 101173

**Barbosa RRB., Coelho PD., Liberato FMG., Vidal PD., de Carvalho RBCO., Melotti RDNC., Donadio MVF.**  
Sleep disorders are distinctively associated with exercise intolerance and sedentary behavior in children with cystic fibrosis  
*Sleep Medicine* 2020; 74: 145 - 151

**Boutou AK., Manika K., Hajimitrova M., Pitsiou G., Giannakopoulou P., Sourla E., Kioumis I.**  
Longitudinal changes in exercise capacity among adult cystic fibrosis patients  
*Advances in Respiratory Medicine* 2020; 88: 420 - 423

**Denford S., Cox NS., Mackintosh KA., McNarry MA., O'Halloran P., Holland AE., Tomlinson OW., Barker AR., Williams CA.**  
Physical activity for cystic fibrosis: perceptions of people with cystic fibrosis, parents and healthcare professionals  
*ERJ Open Research* 2020; 6: 3:00294-2019

**Houchen-Wolloff L., Daynes E., Watt A., Chaplin E., Gardiner N., Singh S.**  
Which functional outcome measures can we use as a surrogate for exercise capacity during remote cardiopulmonary rehabilitation assessments? A rapid narrative review  
*ERJ Open Research* 2020; 6: 4:00526-2020

**Hurley N., Kehoe B., McCaffrey N., Redmond K., Cullen L., Moyna NM.**  
Recommendations to improve physical activity prescription for the cystic fibrosis population: an Irish perspective  
*BMC Health Services Research* 2020; 20: 1:1052

**Ladores S.**  
Applying Pettitmengin's Explicitation Interview Method to Elicit the Lived Experience of Breathing Upon Waking by an Individual With Cystic Fibrosis  
*Journal of Patient Experience* 2020; 7: 856 - 868

**Leite LR., Queiroz KCV., Coelho CC., Vergara AA., Donadio MVF., Aquino ED.**  
Functional performance in the modified shuttle test in children and adolescents with cystic fibrosis  
*Revista Paulista de Pediatria* 2021; 39: ArtNo: e201932

**Savi D., Graziano L., Giordani B., Schiavetto S., De Vito C., Migliara G., Simmonds NJ., Palange P., Elborn JS.**  
New strategies of physical activity assessment in cystic fibrosis: a pilot study  
*BMC Pulmonary Medicine* 2020; 20: 1:285

**Sawyer A., Cavalheri V., Wood J., Hill K.**  
Exercise testing and exercise training within cystic fibrosis centres across Australia and New Zealand: what is considered important and what is current practice?  
*Internal Medicine Journal* 2020; 50: 1091 - 1099

**Torvanger O., Os A., Skjonsberg OH., Edvardsen E.**  
Cardiorespiratory fitness on a treadmill in an adult cystic fibrosis population  
*BMJ Open Sport & Exercise Medicine* 2020; 6: 1:e000765

## Gastroenterology

**Askarpour S., Ayatipour A., Peyvasteh M., Javaherizadeh H.**  
A comparative study between santulli ileostomy and loop ileostomy in neonates with meconium ileus  
*Arquivos Brasileiros de Cirurgia Digestiva* 2020; 33: 3:e1538

**Beaufils F., Mas E., Mittaine M., Adra M., Fayon M., Delhaes L., Clouzeau H., Galode F., Lamireau T., Bui S., Enaud R.**  
Increased Fecal Calprotectin Is Associated with Worse Gastrointestinal Symptoms and Quality of Life Scores in Children with Cystic Fibrosis  
*Journal of Clinical Medicine* 2020; 9: 12:4080

**Bongiovanni A., Manti S., Parisi GF., Papale M., Mule E., Rotolo N., Leonardi S.**  
Focus on gastroesophageal reflux disease in patients with cystic fibrosis  
*World Journal of Gastroenterology* 2020; 26: 6322 - 6334

**Carson SW., Craven KE., Nauen D., Montemayor K., Yarchoan M., Burns WR., Merlo CA., West NE.**  
Rapidly progressive metastatic cholangiocarcinoma in a postpartum patient with cystic fibrosis: a case report  
*BMC Pulmonary Medicine* 2020; 20: 1:298

**Ferre-Aracil C., Gonzalez-Haba M., Tormo-Lanseros B., Gimenez-Alvira L., Jimenez-Garrido M.**  
Distal Intestinal Obstruction Syndrome resolved by dissolution with Coca-Cola (R) via colonoscopy in a cystic fibrosis patient  
*Journal of Cystic Fibrosis* 2020; 19: E43 - E44

**Gelzo M., Iacotucci P., Carnovale V., Castaldo A., Comegna M., Cernera G., Corso G., Castaldo G.**  
Impaired Ratio of Unsaturated to Saturated Non-Esterified Fatty Acids in Saliva from Patients with Cystic Fibrosis  
*Diagnostics* 2020; 10: 11:915

**Gelzo M., Iacotucci P., Sica C., Liguori R., Comegna M., Carnovale V., Dello Russo A., Corso G., Castaldo G.**  
Influence of pancreatic status on circulating plasma sterols in patients with cystic fibrosis  
*Clinical Chemistry and Laboratory Medicine* 2020; 58: 1725 - 1730

**Hough NE., Chapman SJ., Flight WG.**  
Gastrointestinal malignancy in cystic fibrosis  
*Paediatric Respiratory Reviews* 2020; 35: 90 - 92

**Lahiri T., Sullivan JS., Sartorelli KH., Murphy JJ.**  
Delayed Presentation of Meconium Ileus in an Infant With Cystic Fibrosis  
*Pediatrics* 2020; 146: 4:e20193717

**Morales CAM., Gonzalez-Urquijo M., Flores LFM., Quevedo-Fernandez E., Huerta EAG., Hernandez-Torre MMV.**  
Proximal intestinal obstruction syndrome (PIOS) in a patient with cystic fibrosis: A case report  
*Annals of Medicine and Surgery* 2020; 60: 669 - 672

**Sandy NS., Massabki LH., Goncalves AC., Ribeiro AF., Ribeiro JD., Servidoni MDCP., Lomazi EA.**  
Distal intestinal obstruction syndrome: a diagnostic and therapeutic challenge in cystic fibrosis  
*Jornal de Pediatria* 2020; 96: 732 - 740

**Sellers ZM.**  
Pancreatic complications in children with cystic fibrosis  
*Current Opinion in Pediatrics* 2020; 32: 661 - 667



**Smith S., Rowbotham N., Davies G., Gathercole K., Collins SJ., Elliott Z., Herbert S., Allen L., Ng C., Smyth A.**

How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey  
*BMJ Open Respiratory Research* 2020; 7: 1:e000614

**Stefano MA., Poderoso RE., Mainz JG., Ribeiro JD., Ribeiro AF., Lomazi EA.**

Prevalence of constipation in cystic fibrosis patients: a systematic review of observational studies  
*Jornal de Pediatria* 2020; 96: 686 - 692

**Weeks SM.**

Probiotics for people with cystic fibrosis (review)  
*Gastroenterology Nursing* 2020; 43: 474 - 476

## Gene Therapy

**Alton EFWF., Boyd AC., Davies JC., Gill DR., Griesenbach U., Harman TE., Hyde SP., McLachlan G.**

Gene Therapy for Respiratory Diseases: Progress and a Changing Context  
*Human Gene Therapy* 2020; 31: 911 - 916

**Banuls L., Pellicer D., Castillo S., Navarro-Garcia MM., Magallon M., Gonzalez C., Dasi F.**

Gene Therapy in Rare Respiratory Diseases: What Have We Learned So Far?  
*Journal of Clinical Medicine* 2020; 9: 8:2577

**Khamsi R.**

Gene therapy could offer an inclusive cure for cystic fibrosis  
*Nature* 2020; 583: S12 - S14

**Vu A., McCray PB.**

New Directions in Pulmonary Gene Therapy  
*Human Gene Therapy* 2020; 31: 921 - 939

## General Review

**Doull I.**

Cystic fibrosis 2019: Year in review  
*Paediatric Respiratory Reviews* 2020; 35: 95 - 98

**Huegel C., Smaczny C., Eickmeier O., Zielen S., Rohde G.**

Cystic fibrosis  
*Pneumologie* 2020; 17: 223 - 233

## Genetics

**Aluma BE., Sarouk I., Senderowitz H., Cohen-Cyberknoh M., Khazanov N., Dagan A., Bezalel Y., Ashkenazi M., Keler S., Efrati O.**

Phenotypic and molecular characteristics of CF patients carrying the I1234V mutation  
*Respiratory Medicine* 2020; 170: ArtNo: 106027

**Bareil C., Bergougnoux A.**

CFTR gene variants, epidemiology and molecular pathology  
*Archives de Pediatrie* 2020; 27:

**Bieth E., Nectoux J., Girardet A., Gruchy N., Mittre H., Laurans M., Guenet D., Brouard J., Gerard M.**

Genetic counseling for cystic fibrosis: A basic model with new challenges  
*Archives de Pediatrie* 2020; 27:

**Colak Y., Nordestgaard BG., Afzal S.**

Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population  
*European Respiratory Journal* 2020; 56: 3:2000558

**Ferec C., Scotet V.**

Genetics of cystic fibrosis: Basics  
*Archives de Pediatrie* 2020; 27:

**Karimi N., Pour AB., Alibakhshi R., Almasi S.**

Haplotype analysis of the CFTR gene on normal and mutant CFTR genes

*Mutation Research-fundamental and Molecular Mechanisms of Mutagenesis* 2020; 821: ArtNo: 111708

**Kondratyeva E., Efremova A., Melyanovskaya Y., Petrova N., Satsuk N., Bulatenko N., Bukharova T., Zodbinova A., Sherman V., Kashirskaya N., Zinchenko R., Kutsev S., Goldshtein D.**

Clinical and genetic characterization of patients with cystic fibrosis and functional assessment of the chloride channel with the pathogenic variant c.831G > A (p.Trp277\*), described for the first time  
*Gene* 2020; 761: ArtNo: 145023

**Laselva O., McCormack J., Bartlett C., Ip W., Gunawardena TNA., Ouyang H., Eckford PDW., Gonska T., Moraes TJ., Bear CE.**

Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A > G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators  
*Journal of Personalized Medicine* 2020; 10: 4:209

**Laudus N., Audrezet MP., Girodon E., Morris MA., Radojkovic D., Raynal C., Seia M., Stambergova A., Torkler H., Yamamoto R., Dequeker EMC.**

Laboratory reporting on the clinical spectrum of CFTR p.Arg117His: Still room for improvement  
*Journal of Cystic Fibrosis* 2020; 19: 969 - 974

**Masood A., Jacob M., Gu XY., Jabar MA., Benabdelkamel H., Nizami I., Li L., Dasouki M., Rahman AMA.**

Distinctive metabolic profiles between Cystic Fibrosis mutational subclasses and lung function  
*Metabolomics* 2021; 17: 1:4

**Molina M., Yoldi A., Navas P., Ganan M., Vaquero A., del Pico JL., Ramirez JP., Castilla JA.**

Carriers of cystic fibrosis among sperm donors: complete CFTR gene analysis versus CFTR genotyping  
*Fertility and Sterility* 2020; 114: 524 - 534

**Petrova NV., Kashirskaya NY., Krasovskiy SA., Amelina EL., Kondratyeva EI., Marakhonov AV., Vasilyeva TA., Voronkova AY., Sherman VD., Ginter EK., Kutsev SL., Zinchenko RA.**

Clinical Presentation of the c.3844T > C (p.Trp1282Arg, W1282R) Variant in Russian Cystic Fibrosis Patients  
*Genes* 2020; 11: 10:1137

**Silva IAL., Dousova T., Ramalho S., Centeio R., Clarke LA., Railean V., Botelho HM., Holubova A., Valaskova I., Yeh JT., Hwang TC., Farinha CM., Kunzelmann K., Amaral MD.**

Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: The case of S955P and 1717-2A > G  
*Biochimica et Biophysica Acta-Molecular Basis of Disease* 2020; 1866: 11:165905

## Growth & Development

**Atteih SE., Raraigh KS., Blackman SM., Cutting GR., Collaco JM.**

Predictive effects of low birth weight and small for gestational age status on respiratory and nutritional outcomes in cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 888 - 895

**Bonhoure A., Boudreau V., Litvin M., Colomba J., Bergeron C., Mailhot M., Tremblay F., Lavoie A., Rabasa-Lhoret R.**

Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors  
*Clinical Nutrition* 2020; 39: 2910 - 2916

**Holland KJ., Slaven JE., Ren CL., Sanders DB., Bennett WE.**

A Retrospective Cohort Study of Growth in the First 2 Years of Life in Preterm Infants With Cystic Fibrosis  
*Journal of Pediatric Gastroenterology and Nutrition* 2020; 70: 115 - 120

**Medrinal C., Combret Y., Bonnevie T., Gravier FE., Le Roux P., Lamia B., Prieur G., Reyckler G.**

Clinimetric evaluation of muscle function tests for individuals with cystic fibrosis: A systematic review  
*Journal of Cystic Fibrosis* 2020; 19: 981 - 995

**Simon SL., Ferris KA., Durkin K., Riekert K., Duncan C.**

Accuracy of Body Size Estimation in Youth with Cystic Fibrosis and Association with Health-Related Quality of Life  
*Journal of Clinical Psychology in Medical Settings* 2020; 27: 459 - 466

**Wu MLD., Bettermann EL., Arora N., Hunt WR., McCracken C., Tangpricha V.**

Relationship Between Estrogen Treatment and Skeletal Health in Women With Cystic Fibrosis  
*American Journal of the Medical Sciences* 2020; 360: 581 - 590

## Immunology & Inflammation

**Allothaid H., Banjar H., Kebir FM., Alharbi A., Bin-Zuman G.**

The first report on immunoglobulins A, E, G and M levels in cystic fibrosis patients in Saudi Arabia  
*Saudi Journal of Biological Sciences* 2020; 27: 2617 - 2621

**Bampi GB., Rauscher R., Kirchner S., Oliver KE., Bijvelds MJC., Santos LA., Wagner J., Frizzell RA., de Jonge HR., Sorscher EJ., Ignatova Z.**

Global assessment of the integrated stress response in CF patient-derived airway and intestinal tissues  
*Journal of Cystic Fibrosis* 2020; 19: 1021 - 1026

**Bellet MM., Borghi M., Pariano M., Renga G., Stincardini C., D'Onofrio F., Brancorsini S., Garaci E., Costantini C., Romani L.**

Thymosin alpha 1 exerts beneficial extrapulmonary effects in cystic fibrosis  
*European Journal of Medicinal Chemistry* 2021; 209: ArtNo: 112921

**Broad J., Le Doare K., Heath PT., Hallchurch P., Whelan I., Boyd H., Carruthers E., Sharland M., Ladhani S.**

The current state of immunization against Gram-negative bacteria in children: a review of the literature  
*Current Opinion in Infectious Diseases* 2020; 33: 517 - 529

**Burton K., Morris NR., Reid D., Smith D., Kuys S.**

Increased physical activity post-exacerbation is associated with decreased systemic inflammation in cystic fibrosis - An observational study  
*Physiotherapy Theory and Practice* 2020; 36: 1457 - 1465

**Cabrini G., Rimessi A., Borgatti M., Lampronti I., Finotti A., Pinton P., Gambari R.**

Role of Cystic Fibrosis Bronchial Epithelium in Neutrophil Chemotaxis  
*Frontiers in Immunology* 2020; 11: ArtNo: 1438

**Cantin AM., Ouellet C., Cloutier A., McDonald PP.**

Airway Mucins Inhibit Oxidative and Non-Oxidative Bacterial Killing by Human Neutrophils  
*Frontiers in Pharmacology* 2020; 11: ArtNo: 554353

**Collin AM., Lecocq M., Noel S., Detry B., Carlier FM., Nana FA., Bouzin C., Leal T., Vermeersch M., De Rose V., Regard L., Martin E., Burgel PR., Hoton D., Verleden S., Froidure A., Pilette C., Gohy S.**

Lung immunoglobulin A immunity dysregulation in cystic fibrosis  
*Ebiomedicine* 2020; 60: ArtNo: 102974

**Consalvi S., Poce G., Ghelardini C., Mannelli LD., Patrignani P., Bruno A., Anzini M., Calderone V., Martelli A., Testai L., Giordani A., Biava M.**

Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis  
*European Journal of Medicinal Chemistry* 2021; 210: ArtNo: 112983

**Costantini C., Puccetti M., Pariano M., Renga G., Stincardini C., D'Onofrio F., Bellet MM., Cellini B., Giovagnoli S., Romani L.**

Selectively targeting key inflammatory pathways in cystic fibrosis  
*European Journal of Medicinal Chemistry* 2020; 206: ArtNo: 112717

**Degasperi M., Agostinis C., Mardirossian M., Maschio M., Taddio A., Bulla R., Scocchi M.**

The Anti-Pseudomonas Peptide D-BMAP18 Is Active in Cystic Fibrosis Sputum and Displays Anti-Inflammatory In Vitro Activity  
*Microorganisms* 2020; 8: 9:1407

**Eraso IC., Sangiovanni S., Morales EI., Fernandez-Trujillo L.**

Use of monoclonal antibodies for allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis: literature review  
*Therapeutic Advances in Respiratory Disease* 2020; 14: ArtNo: 1753466

**Gardner AL., Haq II., Simpson AJ., Becker KA., Gallagher J., Saint-Criq V., Verdon B., Mavin E., Trigg A., Gray MA., Koulman A., McDonnell MJ., Fisher AJ., Kramer EL., Clancy JP., Ward C., Schuchman EH., Gulbins E., Brodrie M.**

Recombinant Acid Ceramidase Reduces Inflammation and Infection in Cystic Fibrosis  
*American Journal of Respiratory and Critical Care Medicine* 2020; 202: 1133 - 1145

**Gothe F., Schmutz A., Hausler K., Tran NB., Kappler M., Griesse M.**

Treating Allergic Bronchopulmonary Aspergillosis with Short-Term Prednisone and Itraconazole in Cystic Fibrosis  
*Journal of Allergy and Clinical Immunology-in Practice* 2020; 8: 2608

**Hayes E., Murphy MP., Pohl K., Browne N., McQuillan K., Saw L., Foley C., Gargoum F., McElvaney OJ., Hawkins P., Gunaratnam C., McElvaney NG., Reeves EP.**

Altered Degranulation and pH of Neutrophil Phagosomes Impacts Antimicrobial Efficiency in Cystic Fibrosis  
*Frontiers in Immunology* 2020; 11: ArtNo: 600033

**Hildebrandt T., Zawilska A., Trzcionka A., Tanasiewicz M., Mazurek H., Swietochowska E.**

Estimation of Proinflammatory Factors in the Saliva of Adult Patients with Cystic Fibrosis and Dental Caries  
*Medicina-Lithuania* 2020; 56: 11:612

**Hovold G., Lindberg U., Ljungberg JK., Shannon O., Pahlman LI.**

BPI-ANCA is expressed in the airways of cystic fibrosis patients and correlates to platelet numbers and Pseudomonas aeruginosa colonization  
*Respiratory Medicine* 2020; 170: ArtNo: 105994

**Kasam RK., Gajjala PR., Jegga AG., Courtney JA., Randell SH., Kramer EL., Clancy JP., Madala SK.**

Fibrocyte accumulation in the lungs of cystic fibrosis patients  
*Journal of Cystic Fibrosis* 2020; 19: 815 - 822

**Martinez-Aleman S., Bustamante AE., Jimenez-Valdes RJ., Gonzalez GM., Sanchez-Gonzalez A.**

Pseudomonas aeruginosa isolates from cystic fibrosis patients induce neutrophil extracellular traps with different morphologies that could correlate with their disease severity  
*International Journal of Medical Microbiology* 2020; 310: 7:151451

**Nielsen BU., Kolpen M., Jensen PO., Katzenstein T., Pressler T., Ritz C., Mathiesen IHM., Faurholt-Jepsen D.**

Neutrophil count in sputum is associated with increased sputum glucose and sputum L-lactate in cystic fibrosis  
*PLoS One* 2020; 15: 9:e0238524

**Oshalim M., Johansson E., Rabe H., Gilljam M., Lindblad A., Jonsson B.**

Th17 associated cytokines in sputum samples from patients with cystic fibrosis  
*Pathogens and Disease* 2020; 78: 6:ftaa050

**Perrem L., Ratjen F.**

Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis  
*Frontiers in Pharmacology* 2020; 11: ArtNo: 576293

**Rehman T., Thornell IM., Pezzulo AA., Thurman AL., Ibarra GSR., Karp PH., Tan P., Duffey ME., Welsh MJ.**  
TNF alpha and IL-17 alkalize airway surface liquid through CFTR and pendrin  
*American Journal of Physiology-cell Physiology* 2020; 319: C331 - C344

**San Gabriel PT., Liu YY., Schroder AL., Zoellner H., Chami B.**  
The Role of Thiocyanate in Modulating Myeloperoxidase Activity during Disease  
*International Journal of Molecular Sciences* 2020; 21: 17:6450

**Schupp JC., Khanal S., Gomez JL., Sauler M., Adams TS., Chupp GL., Yan XT., Poli S., Zhao YJ., Montgomery RR., Rosas IO., Dela Cruz CS., Bruscia EM., Egan ME., Kaminski N., Britto CJ.**  
Single-Cell Transcriptional Archetypes of Airway Inflammation in Cystic Fibrosis  
*American Journal of Respiratory and Critical Care Medicine* 2020; 202: 1419 - 1429

**Tarique AA., Evron T., Zhang G., Tepper MA., Morshed MM., Andersen ISG., Begum N., Sly PD., Fantino E.**  
Anti-inflammatory effects of lenabasum, a cannabinoid receptor type 2 agonist, on macrophages from cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 823 - 829

**Terra ACG., Salvador EA.**  
In silico integrative analysis predicts relevant properties of exotoxin-derived peptides for the design of vaccines against *Pseudomonas aeruginosa*  
*Infection Genetics and Evolution* 2020; 85: ArtNo: 104424

**Wang GB., Zarodkiewicz P., Valvano MA.**  
Current Advances in Burkholderia Vaccines Development  
*Cells* 2020; 9: 12:2671

**Yadav R., Linnemann RW., Kahlenberg JM., Bridges LS., Stcenko AA., Rada B.**  
IgA autoantibodies directed against self DNA are elevated in cystic fibrosis and associated with more severe lung dysfunction  
*Autoimmunity* 2020; 53: 476 - 484

**Zhang SZ., Shrestha CL., Wisniewski BL., Pham H., Hou XC., Li WQ., Dong YZ., Kopp BT.**  
Consequences of CRISPR-Cas9-Mediated CFTR Knockout in Human Macrophages  
*Frontiers in Immunology* 2020; 11: ArtNo: 1871

## Liver Disease

**Baker RD., Baker SS.**  
Cystic Fibrosis-related Liver Disease: The Next Challenge  
*Journal of Pediatric Gastroenterology and Nutrition* 2020; 71: 421 - 422

**Gobato AO., Vasques ACJ., Ribeiro AF., Yamada RM., Hessel G.**  
Prevalence of hepatic steatosis among children and adolescents with cystic fibrosis and its association with nutritional status  
*Revista Paulista de Pediatria* 2019; 37: 435 - 441

**Hojte C., Jorgensen MH., Jensen F., Katzenstein TL., Skov M.**  
Extended Screening for Cystic Fibrosis-related Liver Disease Including Elastography in Children and Adolescents  
*Journal of Pediatric Gastroenterology and Nutrition* 2020; 71: 663 - 668

**Staufer K.**  
Current Treatment Options for Cystic Fibrosis-Related Liver Disease  
*International Journal of Molecular Sciences* 2020; 21: 22:8586

**Verstegen MMA., Roos FJM., Burka K., Gehart H., Jager M., de Wolf M., Bijvelds MJC., de Jonge HR., Ardisasmita AI., van Huizen NA., Roest HP., de Jonge J., Koch M., Pampaloni F., Fuchs SA., Schene IF., Luider TM., van der Doef HPJ., et al**  
Human extrahepatic and intrahepatic cholangiocyte organoids show region-specific differentiation potential and model cystic fibrosis-related bile duct disease  
*Scientific Reports* 2020; 10: 1:21900

**Wasuwanich P., Karnsakul W.**  
Cystic fibrosis-associated liver disease in children  
*Minerva Pediatrica* 2020; 72: 440 - 447

## Microbiology

**Alatraktchi FA., Svendsen WE., Molin S.**  
Electrochemical Detection of Pyocyanin as a Biomarker for *Pseudomonas aeruginosa*: A Focused Review  
*Sensors* 2020; 20: 18:5218

**Ambroa A., Blasco L., Lopez-Causape C., Trastoy R., Fernandez-Garcia L., Bleriot I., Ponce-Alonso M., Pacios O., Lopez M., Canton R., Kidd TJ., Bou G., Oliver A., Tomas M.**  
Temperate Bacteriophages (Prophages) in *Pseudomonas aeruginosa* Isolates Belonging to the International Cystic Fibrosis Clone (CC274)  
*Frontiers in Microbiology* 2020; 11: ArtNo: 556706

**Balmuri SR., Waters NG., Hegemann J., Kierfeld J., Niepa THR.**  
Material properties of interfacial films of mucoid and nonmucoid *Pseudomonas aeruginosa* isolates  
*Acta Biomaterialia* 2020; 118: 129 - 140

**Bartell JA., Cameron DR., Mojsoska B., Haagensen JAJ., Pressler T., Sommer LM., Lewis K., Molin S., Johansen HK.**  
Bacterial persisters in long-term infection: Emergence and fitness in a complex host environment  
*PloS Pathogens* 2020; 16: 12:e1009112

**Berardis S., Verroken A., Vetillart A., Struyf C., Gilbert M., Gruson D., Gohy S.**  
SARS-CoV-2 seroprevalence in a Belgian cohort of patients with cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 872 - 874

**Bernard KA., Vachon A., Pacheco AL., Burdz T., Wiebe D., Beniac DR., Hiebert SL., Booth T., Doyle DA., Lawson P., Bernier AM.**  
*Pseudoxanthomonas winnipegensis* sp. nov., derived from human clinical materials and recovered from cystic fibrosis and other patient types in Canada, and emendation of *Pseudoxanthomonas spadix*  
Young et al. 2007  
*International Journal of Systematic and Evolutionary Microbiology* 2020; 70: 6313 - 6322

**Bernardy EE., Petit RA., Raghuram V., Alexander AM., Read TD., Goldberg JB.**  
Genotypic and Phenotypic Diversity of *Staphylococcus aureus* Isolates from Cystic Fibrosis Patient Lung Infections and Their Interactions with *Pseudomonas aeruginosa*  
*mBio* 2020; 11: 3:e00735-20

**Beswick E., Amich J., Gago S.**  
Factoring in the Complexity of the Cystic Fibrosis Lung to Understand *Aspergillus fumigatus* and *Pseudomonas aeruginosa* Interactions  
*Pathogens* 2020; 9: 8:2541

**Bezzerra V., Lucca F., Volpi S., Cipolli M.**  
Does cystic fibrosis constitute an advantage in COVID-19 infection?  
*Italian Journal of Pediatrics* 2020; 46: 1:143

**Bonnet P., Le Gal S., Calderon E., Delhaes L., Quinio D., Robert-Gangneux F., Ramel S., Nevez G.**  
*Pneumocystis jirovecii* in Patients With Cystic Fibrosis: A Review  
*Frontiers in Cellular and Infection Microbiology* 2020; 10: ArtNo: 571253

**Brao KJ., Wille BP., Lieberman J., Ernst RK., Shirtliff ME., Harro JM.**  
Scn1b-Transgenic BALB/c Mice as a Model of *Pseudomonas aeruginosa* Infections of the Cystic Fibrosis Lung  
*Infection and Immunity* 2020; 88: 9:e00237-20

**Capaldo C., Beuruelle C., Saliou P., Rault G., Ramel S., Hery-Arnaud G.**  
Investigation of *Stenotrophomonas maltophilia* epidemiology in a French cystic fibrosis center  
*Respiratory Medicine and Research* 2020; 78: ArtNo: 100757

- Chapman KD., Moffett KS.**  
Cystic Fibrosis and COVID-19  
*Southern Medical Journal* 2020; 113: 422
- Christophersen L., Schwartz FA., Lerche CJ., Svanekjaer T., Kragh KN., Laulund AS., Thomsen K., Henneberg KA., Sams T., Høiby N., Moser C.**  
In vivo demonstration of *Pseudomonas aeruginosa* biofilms as independent pharmacological microcompartments  
*Journal of Cystic Fibrosis* 2020; 19: 996 - 1003
- Corvol H., de Miranda S., Lemonnier L., Kemgang A., Gaubert MR., Chiron R., Dalphin ML., Durieu I., Dubus JC., Houdouin V., Prevotat A., Ramel S., Revillion M., Weiss L., Guillot L., Boelle PY., Burgel PR.**  
First Wave of COVID-19 in French Patients with Cystic Fibrosis  
*Journal of Clinical Medicine* 2020; 9: 11:3624
- Cross AR., Csatory EE., Raghuram V., Diggle FL., Whiteley M., Wuest WM., Goldberg JB.**  
The histone-like protein AlgP regulon is distinct in mucoid and nonmucoid *Pseudomonas aeruginosa* and does not include alginate biosynthesis genes  
*Microbiology* 2020; 166: 861 - 866
- Cross AR., Raghuram V., Wang ZH., Dey D., Goldberg JB.**  
Overproduction of the AlgT Sigma Factor Is Lethal to Mucoid *Pseudomonas aeruginosa*  
*Journal of Bacteriology* 2020; 202: 20:e00445-20
- Davis TJ., Karanjia AV., Bhebbe CN., West SB., Richardson M., Bean HD.**  
*Pseudomonas aeruginosa* Volatilome Characteristics and Adaptations in Chronic Cystic Fibrosis Lung Infections  
*MSphere* 2020; 5: 5:e00843-20
- De P., Amin AG., Graham B., Martiniano SL., Caceres SM., Poch KR., Jones MC., Saavedra MT., Malcolm KC., Nick JA., Chatterjee D.**  
Urine lipoarabinomannan as a marker for low-risk of NTM infection in the CF airway  
*Journal of Cystic Fibrosis* 2020; 19: 801 - 807
- de Almeida OGG., Capizzani CPD., Tonani L., Bariao PHG., da Cunha AF., De Martinis ECP., Torres LAGMM., Kress MRV.**  
The Lung Microbiome of Three Young Brazilian Patients With Cystic Fibrosis Colonized by Fungi  
*Frontiers in Cellular and Infection Microbiology* 2020; 10: ArtNo: 598938
- De Biase RV., Cristiani L., Paglia C., Alghisi F., Giordani B., Lucidi V., Bella S.**  
Clinical and microbiological monitoring of Cystic Fibrosis patients, three years of follow-up via Tele-Medicine: an empirical research  
*Clinica Terapeutica* 2020; 171: E381 - E384
- de Jong CCM., Slabbers L., Engel TGP., Yntema JB., van Westreenen M., Crougts PD., Roeleveld N., Brimicombe R., Verweij PE., Meis JF., Merkus PJ.**  
Clinical relevance of *Scedosporium* spp. and *Exophiala dermatitidis* in patients with cystic fibrosis: A nationwide study  
*Medical Mycology* 2020; 58: 859 - 866
- de Oliveira EB., Xisto MIDD., Rollin-Pinheiro R., Rochetti VP., Barreto-Bergter E.**  
Peptidoglycanomannans From *Scedosporium* and *Lomentospora* Species Display Microbicidal Activity Against Bacteria Commonly Present in Cystic Fibrosis Patients  
*Frontiers in Cellular and Infection Microbiology* 2020; 10: ArtNo: 598823
- Dennis JB., Jones AM., Davies EA., Welfare W., Barry PJ., Collier L., Turner A., Bright-Thomas RJ.**  
Influenza B outbreak at an adult cystic fibrosis centre - Clinical impact and factors influencing spread  
*Journal of Cystic Fibrosis* 2020; 19: 808 - 814
- Deschamps E., Schaumann A., Schmitz-Afonso I., Afonso C., De E., Loutelier-Bourhis C., Alexandre S.**  
Membrane phospholipid composition of *Pseudomonas aeruginosa* grown in a cystic fibrosis mucus-mimicking medium  
*Biochimica et Biophysica Acta-biomembranes* 2021; 1863: 1:183482
- Devoto TB., Alava KSH., Pola SJ., Pereda R., Ruboglio E., Finquelievich JL., Cuestas ML.**  
Molecular epidemiology of *Aspergillus* species and other moulds in respiratory samples from Argentinean patients with cystic fibrosis  
*Medical Mycology* 2020; 58: 867 - 873
- Duesberg U., Wosniok J., Naehrlich L., Eschenhagen P., Schwarz C.**  
Risk factors for respiratory *Aspergillus fumigatus* in German Cystic Fibrosis patients and impact on lung function  
*Scientific Reports* 2020; 10: 1:18999
- Dyon-Tafari V., Josse J., Safrani-Lahyani J., Assant-Trouillet S., Chiganne M., Vincent F., Perouse De Montclos M., Doleans-Jordheim A., Laurent F.**  
Clinical evaluation of three chromogenic media for the isolation of *Staphylococcus aureus* in respiratory samples in patients with cystic fibrosis  
*Diagnostic Microbiology and Infectious Disease* 2021; 99: 1:115201
- Engel T., Verweij PE., van den Heuvel J., Wangmo D., Zhang JH., Debets AJM., Snelders E.**  
Parasexual recombination enables *Aspergillus fumigatus* to persist in cystic fibrosis  
*ERJ Open Research* 2020; 6: 4:00020-2020
- Feiler CG., Weiss MS., Blankenfeldt W.**  
The hypothetical periplasmic protein PA1624 from *Pseudomonas aeruginosa* folds into a unique two-domain structure  
*Acta Crystallographica Section F-structural Biology Communications* 2020; 76: 609 - 615
- Garcia-Romero I., Valvano MA.**  
Complete Genome Sequence of *Burkholderia cenocepacia* K56-2, an Opportunistic Pathogen  
*Microbiology Resource Announcements* 2020; 9: 43:e01015-20
- Garrigos T., Neuwirth C., Chapuis A., Bador J., Amoureux L.**  
Development of a database for the rapid and accurate routine identification of *Achromobacter* species by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)  
*Clinical Microbiology and Infection* 2021; 27:
- Gosens R., Hiemstra PS., Adcock IM., Bracke KR., Dickson RP., Hansbro PM., Krauss-Etschmann S., Smits HH., Stassen FRM., Bartel S.**  
Host microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease  
*European Respiratory Journal* 2020; 56: 2:1902320
- Grehn C., Eschenhagen P., Temming S., Duesberg U., Neumann K., Schwarz C.**  
Urban Life as Risk Factor for Aspergillosis  
*Frontiers in Cellular and Infection Microbiology* 2020; 10: ArtNo: 601834
- Haggie S., Fitzgerald DA.**  
Pro con debates in clinical medicine infection prevention and control in cystic fibrosis: One size fits all? The argument in favour  
*Paediatric Respiratory Reviews* 2020; 36: 97 - 99
- Hassan AA., dos Santos SC., Cooper VS., Sa-Correia I.**  
Comparative Evolutionary Patterns of *Burkholderia cenocepacia* and *B. multivorans* During Chronic Co-infection of a Cystic Fibrosis Patient Lung  
*Frontiers in Microbiology* 2020; 11: ArtNo: 574626
- Heirali A., Thornton C., Acosta N., Somayaji R., Lapointe IL., Storey D., Rabin H., Waddell B., Rossi L., Arrieta MC., Surette M., Parkins MD.**  
Sputum microbiota in adults with CF associates with response to inhaled tobramycin  
*Thorax* 2020; 75: 1058 - 1064

**Honda JR.**

Clonally Related Viable Nontuberculous Mycobacteria in Gastric Juice and Sputum in People with Cystic Fibrosis Reply  
*American Journal of Respiratory and Critical Care Medicine* 2020; 202: 1062

**Hoo ZH., Hitchcock L., Curley R., Wildman MJ.**

A comparison of the CFHH criteria against the Leeds criteria in determining the *Pseudomonas aeruginosa* status among adults with cystic fibrosis  
*Respiratory Medicine* 2020; 171: ArtNo: 106103

**Hunt WR., Linnemann RW., Middour-Oxler B.**

Transition Planning for Chronic Illnesses in the Time of COVID-19  
*Journal of Patient Experience* 2020; 7: 848 - 850

**Isler B., Kidd TJ., Stewart AG., Harris P., Paterson DL.**

Achromobacter Infections and Treatment Options  
*Antimicrobial Agents and Chemotherapy* 2020; 64: 11:e01025-20

**Jackson L., DePas W., Morris AJ., Guttman K., Yau YCW., Waters V.**

Visualization of *Pseudomonas aeruginosa* within the Sputum of Cystic Fibrosis Patients  
*Jove-journal of Visualized Experiments* 2020; : 161:e61631

**Kuek LE., Lee RJ.**

First contact: the role of respiratory cilia in host-pathogen interactions in the airways  
*American Journal of Physiology-lung Cellular and Molecular Physiology* 2020; 319: L603 - L619

**Lattanzi C., Messina G., Fainardi V., Tripodi MC., Pisi G., Esposito S.**

Allergic Bronchopulmonary Aspergillosis in Children with Cystic Fibrosis: An Update on the Newest Diagnostic Tools and Therapeutic Approaches  
*Pathogens* 2020; 9: 9:716

**Lau KSK., Yeung CT., Carlsten C.**

Stability of serum precipitins to *Aspergillus fumigatus* for the diagnosis of allergic bronchopulmonary aspergillosis  
*Allergy Asthma and Clinical Immunology* 2020; 16: 1:78

**Laudone TW., Garner L., Kam CW., Esther CR., McKinzie CJ.**

Novel therapies for treatment of resistant and refractory nontuberculous mycobacterial infections in patients with cystic fibrosis  
*Pediatric Pulmonology* 2021; 56:

**Le Govic Y., Havlicek V., Capilla J., Luptakova D., Dumas D., Papon N., Le Gal S., Bouchara JP., Vandeputte P.**

Synthesis of the Hydroxamate Siderophore N-alpha-Methylcoprogen B in *Scenedosporium apiospermum* Is Mediated by sidD Ortholog and Is Required for Virulence  
*Frontiers in Cellular and Infection Microbiology* 2020; 10: ArtNo: 587909

**Leven C., Schutz S., Audrezet MP., Nowak E., Meijer L., Montier T.**

Non-Linear Pharmacokinetics of Oral Roscovitine (Seliciclib) in Cystic Fibrosis Patients Chronically Infected with *Pseudomonas aeruginosa*: A Study on Population Pharmacokinetics with Monte Carlo Simulations  
*Pharmaceutics* 2020; 12: 11:1087

**Loman BR., Shrestha CL., Thompson R., Groner JA., Mejias A., Ruoff KL., O'Toole GA., Bailey MT., Kopp BT.**

Age and environmental exposures influence the fecal bacteriome of young children with cystic fibrosis  
*Pediatric Pulmonology* 2020; 55: 1661 - 1670

**Manti S., Parisi GF., Papale M., Licari A., Chiappini E., Mule E., Rotolo N., Leonardi S.**

Allergic bronchopulmonary aspergillosis in children  
*Pediatric Allergy and Immunology* 2020; 31:

**Mantovani RP., Sandri A., Boaretti M., Burlacchini G., Li Vigni V., Scarazzai M., Melotti P., Signoretto C., Leo MM.**

Longitudinal monitoring of sinonasal and oral bacterial reservoirs to prevent chronic lung infection in people with cystic fibrosis  
*ERJ Open Research* 2020; 6: 3:00115-2020

**Margalit A., Carolan JC., Sheehan D., Kavanagh K.**

The *Aspergillus fumigatus* Secretome Alters the Proteome of *Pseudomonas aeruginosa* to Stimulate Bacterial Growth: Implications for Co- infection  
*Molecular & Cellular Proteomics* 2020; 19: 1346 - 1359

**Martin-Souto L., Buldain I., Areitio M., Aparicio-Fernandez L., Antoran A., Bouchara JP., Martin-Gomez MT., Rementeria A., Hernando FL., Ramirez-Garcia A.**

ELISA Test for the Serological Detection of *Scenedosporium/Lomentospora* in Cystic Fibrosis Patients  
*Frontiers in Cellular and Infection Microbiology* 2020; 10: ArtNo: 602089

**Martina PF., Martinez M., Rivas S., Leguizamon L., Von Specht M., Ferreras J.**

*Burkholderia cepacia* complex: 11 years of surveillance in patients with Cystic Fibrosis in Posadas, Argentina  
*Revista Argentina de Microbiologia* 2020; 52: 176 - 182

**Maurice TSF., Nazareth D., McCann C., Walshaw M.**

*Mycobacterium Simiae* Infection in a Person With Cystic Fibrosis  
*Cureus* 2020; 12: 10:e11062

**McClenaghan E., Cosgriff R., Brownlee K., Ahern S., Burgel PR., Byrnes CA., Colombo C., Corvol H., Cheng SY., Daneau G., Elbert A., Faro A., Goss CH., Gulmans V., Gutierrez H., de Monestrol I., Jung A., Justus LN., Kashirskaya N., et al**

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 868 - 871

**Menetrey Q., Dupont C., Chiron R., Jumas-Bilak E., Marchandin H.**

High Occurrence of Bacterial Competition Among Clinically Documented Opportunistic Pathogens Including *Achromobacter xylosoxidans* in Cystic Fibrosis  
*Frontiers in Microbiology* 2020; 11: ArtNo: 558160

**Menetrey Q., Dupont C., Chiron R., Marchandin H.**

Emerging bacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis from a microbiologist's perspective  
*Revue des Maladies Respiratoires* 2020; 37: 561 - 571

**Menzel P., Schwarzer R., Helmuth J., Friesen I.**

Draft Genome Sequence of *Mycobacteroides* sp. Strain LB1, Isolated from the Sputum of a Cystic Fibrosis Patient  
*Microbiology Resource Announcements* 2020; 9: 47:e00797-20

**Meyer VMC., Siqueira MM., Costa PFBM., Caetano BC., Lopes JCO., Folescu TW., Motta FD.**

Clinical impact of respiratory virus in pulmonary exacerbations of children with Cystic Fibrosis  
*PLoS One* 2020; 15: 10:e0240452

**Mielko KA., Jablonski SJ., Wojtowicz W., Milczewska J., Sands D., Lukaszewicz M., Mlynarz P.**

Possible metabolic switch between environmental and pathogenic *Pseudomonas aeruginosa* strains: H-1 NMR based metabolomics study  
*Journal of Pharmaceutical and Biomedical Analysis* 2020; 188: ArtNo: 113369

**Mingione A., Ottaviano E., Barcella M., Merelli I., Rosso L., Armeni T., Cirilli N., Ghidoni R., Borghi E., Signorelli P.**

Cystic Fibrosis Defective Response to Infection Involves Autophagy and Lipid Metabolism  
*Cells* 2020; 9: 8:1845

**Mirza AA., Rad EJ., Mohabir PK.**

Cystic fibrosis and COVID-19: Care considerations  
*Respiratory Medicine Case Reports* 2020; 31: ArtNo: 101226

**Mondejar-Lopez P., Quintana-Gallego E., Giron-Moreno RM., Cortell-Aznar I., de Valbuena-Maiz MR., Diab-Caceres L., Prados-Sanchez C., Alvarez-Fernandez A., Garcia-Marcos PW., Penalver-Mellado C., Pastor-Vivero MD., Oliveira C., et al**

Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey  
*Respiratory Medicine* 2020; 170: ArtNo: 106062

- Moore JE., Millar BC.**  
Comparison of four agar media for the enumeration of the Mycobacterium abscessus complex  
*International Journal of Mycobacteriology* 2020; 9: 289 - 292
- Morgan BG., Warren P., Mewis RE., Rivett DW.**  
Bacterial dominance is due to effective utilisation of secondary metabolites produced by competitors  
*Scientific Reports* 2020; 10: 1:2316
- Okoliegbe IN., Hijazi K., Cooper K., Ironside C., Gould IM.**  
Longitudinal Surveillance and Combination Antimicrobial Susceptibility Testing of Multidrug-Resistant Achromobacter Species from Cystic Fibrosis Patients  
*Antimicrobial Agents and Chemotherapy* 2020; 64: 11:e01467-20
- Olivares E., Tasse J., Badel-Berchoux S., Provot C., Prevost G., Bernardi T.**  
Clinical Biofilm Ring Test(R) Reveals the Potential Role of beta-Lactams in the Induction of Biofilm Formation by P. aeruginosa in Cystic Fibrosis Patients  
*Pathogens* 2020; 9: 12:1065
- Orazi G., Jean-Pierre F., O'Toole GA.**  
Pseudomonas aeruginosa PA14 Enhances the Efficacy of Norfloxacin against Staphylococcus aureus Newman Biofilms  
*Journal of Bacteriology* 2020; 202: 18:e00159-20
- Papa R., Garzoli S., Vrenna G., Sabatino M., Sapienza F., Relucanti M., Donfrancesco O., Fiscarelli EV., Artini M., Selan L., Ragno R.**  
Essential Oils Biofilm Modulation Activity, Chemical and Machine Learning Analysis. Application on Staphylococcus aureus Isolates from Cystic Fibrosis Patients  
*International Journal of Molecular Sciences* 2020; 21: 23:9258
- Pecho-Silva S., Navarro-Solsol AC., Panduro-Correa V., Arteaga-Livias K., Rodriguez-Morales AJ., Dhama K.**  
COVID-19 and Cystic Fibrosis: Diagnostic Difficulties or Incorrect Methods?  
*Journal of Pure and Applied Microbiology* 2020; 14: 1681 - 1685
- Perault AL., Chandler CE., Rasko DA., Ernst RK., Wolfgang MC., Cotter PA.**  
Host Adaptation Predisposes Pseudomonas aeruginosa to Type VI Secretion System-Mediated Predation by the Burkholderia cepacia Complex  
*Cell Host & Microbe* 2020; 28: 534 - +
- Pickrum AM., DeLeon O., Dirck A., Tessmer MH., Riegert MO., Biller JA., Ledebner NA., Kirby JR., Frank DW.**  
Achromobacter xylosoxidans Cellular Pathology Is Correlated with Activation of a Type III Secretion System  
*Infection and Immunity* 2020; 88: 7:e00136-20
- Pimenta AI., Mil-Homens D., Pinto SN., Fialho AM.**  
Phenotypic characterization of trimeric autotransporter adhesin-defective bcaC mutant of Burkholderia cenocepacia: cross-talk towards the histidine kinase BCAM0218  
*Microbes and Infection* 2020; 22: 457 - 466
- Pollak M., Shaw M., Wilson D., Grasmann H., Ratjen F.**  
Bronchodilator responsiveness in children with cystic fibrosis and allergic bronchopulmonary aspergillosis  
*European Respiratory Journal* 2020; 56: 2:2000175
- Price EP., Arango VS., Kidd TJ., Fraser TA., Nguyen TK., Bell SC., Sarovich DS.**  
Duplex real-time PCR assay for the simultaneous detection of Achromobacter xylosoxidans and Achromobacter spp.  
*Microbial Genomics* 2020; 6: 7:000406
- Pust MM., Wiehlmann L., Davenport C., Rudolf I., Dittrich AM., Tummler B.**  
The human respiratory tract microbial community structures in healthy and cystic fibrosis infants  
*NPJ Biofilms and Microbiomes* 2020; 6: 1:61
- Radonjic A., Pakhale S., Aaron SD., Earlam K., Gaudet E., Gomes MM., Gupta A., Mulpuru S., Chin M.**  
Organizing pneumonia secondary to Exophiala dermatitidis in cystic fibrosis: A case report  
*Journal of Cystic Fibrosis* 2020; 19: E33 - E35
- Raghuvanshi R., Vasco K., Vazquez-Baeza Y., Jiang LJ., Morton JT., Li DX., Gonzalez A., Goldasich LD., Humphrey G., Ackermann G., Swafford AD., Conrad D., Knight R., Dorrestein PC., Quinn RA.**  
High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic Therapy  
*Msystems* 2020; 5: 3:e00292-20
- Rosales-Reyes R., Rodriguez-Alvarado M., Lezana-Fernandez JL., Sanchez-Lozano JY., Gayosso-Vazquez C., Jarillo-Quijada MD., Toledano-Tableros JE., Arredondo-Mercado MJ., Alcantar-Curiel MD., Lincopan N., Vidal JE., Lascurain R., et al**  
Pseudomonas aeruginosa Isolates From a Cohort of Mexican Children With Cystic Fibrosis Show Adaptation to a Chronic Phenotype  
*Pediatric Infectious Disease Journal* 2020; 39: 899 - 906
- Sarges NF., Rodrigues YC., Furlaneto IP., de Melo MVH., Brabo GLD., Lopes KCM., Quaresma AJPG., Lima LNG., Lima KVB.**  
Pseudomonas aeruginosa Type III Secretion System Virulotypes and Their Association with Clinical Features of Cystic Fibrosis Patients  
*Infection and Drug Resistance* 2020; 13: 3771 - 3781
- Sass A., Coenye T.**  
Complete Genome Sequence of Pseudomonas aeruginosa Strain AA2 (LMG 27630), an Early Isolate Recovered from the Airway of a German Cystic Fibrosis Patient  
*Microbiology Resource Announcements* 2020; 9: 26:e00526-20
- Scagnolari C., Bitossi C., Frasca F., Viscido A., Brazzini G., Trancassini M., Pietropaolo V., Midulla F., Cimino G., Palange P., Pierangeli A., Antonelli G.**  
Differential toll like receptor expression in cystic fibrosis patients' airways during rhinovirus infection  
*Journal of Infection* 2020; 81: 726 - 735
- Shoaib A., Lone NA., Yi X.**  
Co-infection with Pseudomonas aeruginosa impacts virulence of Staphylococcus aureus and intensifies the severity of infection  
*Pakistan Journal of Pharmaceutical Sciences* 2020; 33: 1933 - 1937
- Smyth AR., Smith SJ., Rowbotham NJ.**  
Infection prevention and control in cystic fibrosis: One size fits all The argument against  
*Paediatric Respiratory Reviews* 2020; 36: 94 - 96
- Soares A., Alexandre K., Etienne M.**  
Tolerance and Persistence of Pseudomonas aeruginosa Biofilms Exposed to Antibiotics: Molecular Mechanisms, Antibiotic Strategies and Therapeutic Perspectives  
*Frontiers in Microbiology* 2020; 11: ArtNo: 2057
- Somayaji R., Yau YCW., Tullis E., LiPuma JJ., Ratjen F., Waters V.**  
Clinical Outcomes Associated with Burkholderia cepacia Complex Infection in Patients with Cystic Fibrosis  
*Annals of the American Thoracic Society* 2020; 17: 1542 - 1548
- Soret P., Vandenborgh LE., Francis F., Coron N., Enaud R., Avalos M., Schaevebeke T., Berger P., Fayon M., Thiebaut R., Delhaes L., Chabe M., Audebert C., Durand-Joly L., Boldron A., Pin I., Cognet O., Pelloux H., et al**  
Respiratory mycobiome and suggestion of inter-kingdom network during acute pulmonary exacerbation in cystic fibrosis  
*Scientific Reports* 2020; 10: 1:3589
- Sousa SA., Seixas AMM., Mandal M., Rodriguez-Ortega MJ., Leitao JH.**  
Characterization of the Burkholderia cenocepacia J2315 Surface-Exposed Immunoproteome  
*Vaccines* 2020; 8: 3:509
- Sposito F., McNamara PS., Hedrich CM.**  
Vasculitis in Cystic Fibrosis  
*Frontiers in Pediatrics* 2020; 8: ArtNo: 585275
- Sun J., LaRock DL., Skowronski EA., Kimmey JM., Olson J., Jiang ZZ., O'Donoghue AJ., Nizet V., LaRock CN.**  
The Pseudomonas aeruginosa protease LasB directly activates IL-1 beta  
*Ebiomedicine* 2020; 60: ArtNo: 102984

**Sunman B., Tural DA., Ozsezen B., Emiralioğlu N., Yalcin E., Özcelik U.**

Current Approach in the Diagnosis and Management of Allergic Bronchopulmonary Aspergillosis in Children With Cystic Fibrosis  
*Frontiers in Pediatrics* 2020; 8: ArtNo: 582964

**Teran LC., Distefano M., Bellich B., Petrosino S., Bertoncin P., Cescutti P., Sblattero D.**

Proteomic Studies of the Biofilm Matrix including Outer Membrane Vesicles of *Burkholderia multivorans* C1576, a Strain of Clinical Importance for Cystic Fibrosis  
*Microorganisms* 2020; 8: 11:1826

**Teri A., Sottotetti S., Arghittu M., Girelli D., Biffi A., D'Accio M., Dacco V., Gambazza S., Pizzamiglio G., Trovato A., Tortoli E., Colombo C., Cariani L.**

Molecular characterization of *Mycobacterium abscessus* subspecies isolated from patients attending an Italian Cystic Fibrosis Centre  
*New Microbiologica* 2020; 43: 127 - 132

**Thi MTT., Wibowo D., Rehm BHA.**

*Pseudomonas aeruginosa* Biofilms  
*International Journal of Molecular Sciences* 2020; 21: 22:8671

**Vandenbussche I., Sass A., Pinto-Carbo M., Mannweiler O., Eberl L., Coenye T.**

DNA Methylation Epigenetically Regulates Gene Expression in *Burkholderia cenocepacia* and Controls Biofilm Formation, Cell Aggregation, and Motility  
*Mosphere* 2020; 5: 4:e00455-20

**Vandeputte P., de Bernonville TD., Le Govic Y., Le Gal S., Nevez G., Papon N., Bouchara JP.**

Comparative transcriptome analysis unveils the adaptive mechanisms of *Scedosporium apiospermum* to the microenvironment encountered in the lungs of patients with cystic fibrosis  
*Computational and Structural Biotechnology Journal* 2020; 18: 3468 - 3483

**Verma S., Mathew JL., Ray P.**

Comparison of respiratory pathogen colonization and antimicrobial susceptibility in people with cystic fibrosis bronchiectasis versus non-cystic fibrosis bronchiectasis: a protocol for a systematic review  
*Systematic Reviews* 2021; 10: 1:7

**Walczak A., Wilks K., Shakhovskoy R., Baird T., Schlebusch S., Taylor C., Reid D., Choong K.**

COVID-19 in a complex obstetric patient with cystic fibrosis  
*Infection Disease & Health* 2020; 25: 239 - 241

**Wang HH., Cisse OH., Bolig T., Drake SK., Chen Y., Strich JR., Youn JH., Okoro U., Rosenberg AZ., Sun JF., LiPuma JJ., Suffredini AF., Dekker JP.**

A Phylogeny-Informed Proteomics Approach for Species Identification within the *Burkholderia cepacia* Complex  
*Journal of Clinical Microbiology* 2020; 58: 11:e01741-20

**Ward C., Al Momani H., Perry A., Perry JD., Krishnan A., Jones R., Griffin M., Pearson J., Bourke S.**

Clonally Related Viable Nontuberculous *Mycobacteria* in Gastric Juice and Sputum in People with Cystic Fibrosis  
*American Journal of Respiratory and Critical Care Medicine* 2020; 202: 1061

**Webster G., Jones C., Mullins AJ., Mahenthalingam E.**

A rapid screening method for the detection of specialised metabolites from bacteria: Induction and suppression of metabolites from *Burkholderia* species  
*Journal of Microbiological Methods* 2020; 178: ArtNo: 106057

**Wiersma CJ., Belardinelli JM., Avanzi C., Angala SK., Everall I., Angala B., Kendall E., de Moura VCN., Verma D., Benoit J., Brown KP., Jones V., Malcolm KC., Strong M., Nick JA., Floto RA., Parkhill J., Ordway DJ., Davidson RM., M**

Cell Surface Remodeling of *Mycobacterium abscessus* under Cystic Fibrosis Airway Growth Conditions  
*ACS Infectious Diseases* 2020; 6: 2143 - 2154

**Wong KSK., Dhaliwal S., Bilawka J., Srigley JA., Champagne S., Romney MG., Tilley P., Sadarangani M., Zlosnik JEA., Chilvers MA.**

Matrix-assisted laser desorption/ionization time-of-flight MS for the accurate identification of *Burkholderia cepacia* complex and *Burkholderia gladioli* in the clinical microbiology laboratory  
*Journal of Medical Microbiology* 2020; 69: 1105 - 1113

**Wurster S., Sass G., Albert ND., Nazik H., Deziel E., Stevens DA., Kontoyiannis DP.**

Live imaging and quantitative analysis of *Aspergillus fumigatus* growth and morphology during inter-microbial interaction with *Pseudomonas aeruginosa*  
*Virulence* 2020; 11: 1329 - 1336

**Zemke AC., D'Amico EJ., Snell EC., Torres AM., Kasturiarachi N., Bomberger JM.**

Dispersal of Epithelium-Associated *Pseudomonas aeruginosa* Biofilms  
*Mosphere* 2020; 5: 4:e00630-20

**Zlosnik JEA., Henry DA., Hird TJ., Hickman R., Campbell M., Cabrera A., Chiavegatti GL., Chilvers MA., Sadarangani M.**

Epidemiology of *Burkholderia* Infections in People with Cystic Fibrosis in Canada between 2000 and 2017  
*Annals of the American Thoracic Society* 2020; 17: 1549 - 1557

## Nutrition

**Bilan N., Marefat E., Nikniaz L., Farhangi MA., Nikniaz Z.**

Does synbiotic supplementation affect the quality of life in children with cystic fibrosis? A pilot randomized controlled clinical trial  
*BMC Nutrition* 2020; 6: 1:44

**Bonhoure A., Boudreau V., Litvin M., Colomba J., Bergeron C., Mailhot M., Tremblay F., Lavoie A., Rabasa-Lhoret R.**

Overweight, obesity and significant weight gain in adult patients with cystic fibrosis association with lung function and cardiometabolic risk factors  
*Clinical Nutrition* 2020; 39: 2910 - 2916

**Bozic M., Goss CH., Tirouvanziam RM., Baines A., Kloster M., Antoine L., Borowitz D., Schwarzenberg SJ.**

Oral Glutathione and Growth in Cystic Fibrosis: A Multicenter, Randomized, Placebo-controlled, Double-blind Trial  
*Journal of Pediatric Gastroenterology and Nutrition* 2020; 71: 771 - 777

**Dara N., Imanzadeh F., Madani SR., Tajalli S., Rouhani P., Hosseini A., Ashtijoo P., Hatefi S., Farsani ZF., Hajipour M., Khatami K., Gorji FA., Sayyari A., Olang B.**

The Effect of Nutritional Consultation on the Level of Malnutrition and Growth Indices in Children with Cystic Fibrosis  
*International Journal of Pediatrics* 2020; 8: 11793 - 11801

**Declercq D., Van Braeckel E., Marchand S., Van Daele S., Van Biervliet S.**

Sodium Status and Replacement in Children and Adults Living with Cystic Fibrosis: A Narrative Review  
*Journal of the Academy of Nutrition and Dietetics* 2020; 120: 1517 - 1529

**Escobedo-Monge MF., Barrado E., Vicente CA., Escobedo-Monge MA., Torres-Hinojal MC., Marugan-Miguelsanz JM., del Rio MPR.**

Copper and Copper/Zinc Ratio in a Series of Cystic Fibrosis Patients  
*Nutrients* 2020; 12: 11:3344

**Lopez-Neyra A., Suarez L., Munoz M., de Blas A., de Valbuena MR., Garriga M., Calvo J., Ribes C., Moreno RG., Maiz L., Gonzalez D., Bousono C., Manzanares J., Pastor O., Martinez-Botas J., del Campo R., Canton R., Roy G., Menacho M.**

Long-term docosahexaenoic acid (DHA) supplementation in cystic fibrosis patients: a randomized, multi-center, double-blind, placebo-controlled trial  
*Prostaglandins Leukotrienes and Essential Fatty Acids* 2020; 162: ArtNo: 102186

**Neri LDL., Bergamaschi DP., da Silva LVRF.**  
Evaluation of nutritional status in patients with cystic fibrosis according to age group  
*Revista Paulista de Pediatria* 2019; 37: 58 - 64

**Okebukola PO., Kansra S., Barrett J.**  
Vitamin E supplementation in people with cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2020; : 9:CD009422

**Poulimeneas D., Grammatikopoulou MG., Devetzi P., Petrocheilou A., Kaditis AG., Papamitsou T., Doudounakis SE., Vassilakou T.**

Adherence to Dietary Recommendations, Nutrient Intake Adequacy and Diet Quality among Pediatric Cystic Fibrosis Patients: Results from the GreeCF Study  
*Nutrients* 2020; 12: 10:3126

**Somaraju URR., Solis-Moya A.**  
Pancreatic enzyme replacement therapy for people with cystic fibrosis  
*Cochrane Database of Systematic Reviews* 2020; : 8:CD008227

## Physiotherapy

**Benoit CM., Christensen E., Nickel AJ., Shogren S., Johnson M., Thompson EF., McNamara J.**  
Objective Measures of Vest Therapy Adherence Among Pediatric Subjects With Cystic Fibrosis  
*Respiratory Care* 2020; 65: 1831 - 1837

**Donadio MVE., Campos NE., Vendrusculo FM., Stofella AM., Almeida ACD., Ziegler B., Schivinski CIS., Santuzzi CH., Sarges EDNF., Goncalves FM., Ribeiro MAGD., Santana NN., de Paiva SB., de Godoy VCWP., Aquino ED.**  
Respiratory physical therapy techniques recommended for patients with cystic fibrosis treated in specialized centers  
*Brazilian Journal of Physical Therapy* 2020; 24: 532 - 538

**Montero-Ruiz A., Fuentes LA., Ruiz EP., Soler NGA., Rius-Diaz F., Aguilera PC., Frias JP., Martin-Montanez E.**  
Effects of music therapy as an adjunct to chest physiotherapy in children with cystic fibrosis: A randomized controlled trial  
*PLoS One* 2020; 15: 10:e0241334

**Raywood E., Douglas H., Kapoor K., Filipow N., Murray N., O'Connor R., Stott L., Saul G., Kuzhagaliyev T., Davies G., Liakhovich O., Van Schaik T., Furtuna B., Booth J., Shannon H., Bryon M., Main E.**  
Protocol for Project Fizzyo, an analytic longitudinal observational cohort study of physiotherapy for children and young people with cystic fibrosis, with interrupted time-series design  
*BMJ Open* 2020; 10: 10:e039587

**Voldby C., Green K., Kongstad T., Ring AM., Sandvik RM., Skov M., Buchvald F., Pressler T., Nielsen KG.**  
Lung clearance index-triggered intervention in children with cystic fibrosis - A randomised pilot study  
*Journal of Cystic Fibrosis* 2020; 19: 934 - 941

## Psychosocial

**Balfour-Lynn IM., Khan K., Pentayya N., Pheasant C., Bentley S., Makhecha S.**  
Initiating Self-Administration of Medicines for in-patients with cystic fibrosis  
*Archives of Disease in Childhood* 2020; 105: 986 - 990

**Bonfim BS., de Melo VM., Fontenelle FM., Souza EL.**  
Treatment adherence among children and adolescents in a cystic fibrosis reference center  
*Revista Paulista de Pediatria* 2020; 38: ArtNo: e201833

**Byars KC., Chini B., Hente E., Amin R., Boat T.**  
Sleep disturbance and sleep insufficiency in primary caregivers and their children with cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 777 - 782

**Calthorpe RJ., Smith SJ., Rowbotham NJ., Leighton PA., Davies G., Daniels T., Gathercole K., Allen L., Elliott ZC., Smyth AR.**  
What effective ways of motivation, support and technologies help people with cystic fibrosis improve and sustain adherence to treatment?  
*BMJ Open Respiratory Research* 2020; 7: 1:e000601

**Cox A., Pritchard C.**  
Hearing the Voice of a Shadow Child: Healthy Siblings Experience of Cystic Fibrosis and Other Life-Threatening Conditions  
*Journal of Patient Experience* 2020; 7: 878 - 881

**del Corral T., La Touche R., Iranzo MACI., Olmos R., Blanco-Royano F., Lopez-de-Uralde-Villanueva I.**  
Development and Validation of the AdT-Physio Scale: A Tool to Assess Adherence and Perception of Physical Therapist Intervention in Patients With Cystic Fibrosis  
*Physical Therapy* 2020; 100: 2063 - 2074

**Drabble SJ., O'Cathain A., Scott AJ., Arden MA., Keating S., Hutchings M., Maguire C., Wildman M.**  
Mechanisms of Action of a Web-Based Intervention With Health Professional Support to Increase Adherence to Nebulizer Treatments in Adults With Cystic Fibrosis: Qualitative Interview Study  
*Journal of Medical Internet Research* 2020; 22: 10:e16782

**Esteban-Romani L., Botija-Yague M.**  
Quality management in patients associations. Diagnosis in the Spanish federation of cystic fibrosis  
*Trabajo Social Global-global Social Work* 2020; 10: 201 - 223

**Georgiopoulos AM., Christon LM., Filigno SS., Mueller A., Priour MG., Boat TF., Smith BA.**  
Promoting emotional wellness in children with CF, part II: Mental health assessment and intervention  
*Pediatric Pulmonology* 2021; 56:

**Graziano S., Spano B., Majo F., Righelli D., Vincenzina L., Quittner A., Tabarini P.**  
Rates of depression and anxiety in Italian patients with cystic fibrosis and parent caregivers: Implementation of the Mental Health Guidelines  
*Respiratory Medicine* 2020; 172: ArtNo: 106147

**Havermans T., Houben J., Vermeulen F., Boon M., Proesmans M., Lorent N., de Soir E., Vos R., Dupont L.**  
The impact of the COVID-19 pandemic on the emotional well-being and home treatment of Belgian patients with cystic fibrosis, including transplanted patients and paediatric patients  
*Journal of Cystic Fibrosis* 2020; 19: 880 - 887

**Hind D., Drabble SJ., Arden MA., Mandefield L., Waterhouse S., Maguire C., Cantrill H., Robinson L., Beaver D., Scott A., Keating S., Hutchings M., Bradley J., Nightingale J., Allenby MI., Dewar J., Whelan P., Ainsworth J., et al**  
Feasibility study for supporting medication adherence for adults with cystic fibrosis: mixed-methods process evaluation  
*BMJ Open* 2020; 10: 10:e039089

**Jackson AD., Kirwan L., Gibney S., Jeleniewska P., Fletcher G., Doyle G.**  
Associations between health literacy and patient outcomes in adolescents and young adults with cystic fibrosis  
*European Journal of Public Health* 2020; 30: 112 - 118

**Jeffrey A., Andracchio L., Dvorak M., Lomas P., Smith B., Borowitz D.**  
Virtual Peer Support for People With Cystic Fibrosis and Their Family Members: A Program Evaluation  
*Journal of Patient Experience* 2020; 7: 1748 - 1754

**Kidd KM., Sequeira GM., Voss RV., Weiner DJ., Ramsey BW., Jain R., Kazmerski TM.**  
Caring for gender diverse youth with cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 1018 - 1020

**Mueller AE., Georgiopoulos AM., Reno KL., Roach CM., Kvam CM., Quittner AL., Lomas P., Smith BA., Filigno SS.**  
Introduction to Cystic Fibrosis for Mental Health Care Coordinators and Providers: Collaborating to Promote Wellness  
*Health & Social Work* 2020; 45: 202 - 210



**Prieur MG., Christon LM., Mueller A., Smith BA., Georgiopoulos AM., Boat TF., Filigno SS.**

Promoting emotional wellness in children with cystic fibrosis, Part I: Child and family resilience  
*Pediatric Pulmonology* 2021; 56:

**Radice RP., Radice OA., Radice MR., Radice CA.**

Quality of life in adolescents aged 14 to 18 years with cystic fibrosis at the cystic fibrosis foundation, Paraguay  
*Pediatrics* 2020; 47: 159 - 164

**Radtke T., Haile SR., Dressel H., Benden C.**

Recommended shielding against COVID-19 impacts physical activity levels in adults with cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 875 - 879

**Santana NN., Chaves CRMD., Goncalves CP., Gomes SD.**

Factors associated to quality of life in children and adolescents with cystic fibrosis  
*Revista Paulista de Pediatria* 2020; 38: ArtNo: e201839

**Smith A., Barry M.**

Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: a retrospective analysis of a national pharmacy claims database  
*BMJ Open* 2020; 10: 11:e040806

**Souza TCF., Correa AJS., de Santana ME., Pimentel IMD., Carvalho JN.**

Experiences of family members of children with cystic fibrosis under the light of Callista Roy  
*Revista Brasileira de Enfermagem* 2020; 73:

**Stacel T., Jaworska I., Zawadzki F., Wajda-Pokrontka M., Tatoi Z., Urlik M., Neckr M., Latos M., Szywacz W., Szczerba A., Antocznyk R., Pioro A., Przybylowska P., Zembala M., Ochman M.**

Assessment of Quality of Life Among Patients After Lung Transplantation: A Single-Center Study  
*Transplantation Proceedings* 2020; 52: 2165 - 2172

**Van Citters AD., Gifford AH., Brady C., Dunitz JM., Elmhirst M., Flath J., Laguna TA., Moore B., Prickett ML., Riordan M., Savant AP., Gore W., Jian S., Soper M., Marshall BC., Nelson EC., Sabadosa KA.**

Formative evaluation of a dashboard to support coproduction of healthcare services in cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 768 - 776

## Pulmonology

**Adewale AT., Libby EF., Fu LW., Lenzie A., Boitet ER., Birket SE., Petty CF., Johns JD., Mazur M., Tearney GJ., Copeland D., Durham C., Rowe SM.**

Novel Therapy of Bicarbonate, Glutathione, and Ascorbic Acid Improves Cystic Fibrosis Mucus Transport  
*American Journal of Respiratory Cell and Molecular Biology* 2020; 63: 362 - 373

**Atag E., Krivec U., Ersu R.**

Non-invasive Ventilation for Children With Chronic Lung Disease  
*Frontiers in Pediatrics* 2020; 8: ArtNo: 561639

**Biciusca V., Petrescu IO., Singer CE., Oancea AG., Petrescu AM., Stan IS., Durand P., Taisescu CI., Dumitrescu D., Dobrescu MA., Udristoiu I., Tudorascu DR., Petrescu F.**

Multidisciplinary approach to patients with manifestations and pulmonary complications of cystic fibrosis  
*Romanian Journal of Morphology and Embryology* 2020; 61: 397 - 406

**Bongers KS., De Cardenas J.**

Endobronchial valve treatment of persistent alveoleopleural fistulae in a patient with cystic fibrosis and empyema  
*Journal of Cystic Fibrosis* 2020; 19: E36 - E38

**Brajer-Luftmann B., Stelmach-Mardas M., Mardas M., Grabicki M., Batura-Gabryel H., Piorunek T.**

Should the dosage of propofol be higher and independent of immunosuppressive therapy in adult cystic fibrosis patients undergoing sedation during flexible video bronchoscopy?  
*European Review for Medical and Pharmacological Sciences* 2020; 24: 11900 - 11908

**Carzino R., Frayman KB., King L., Vidmar S., Ranganathan S.**

Regional differences in infection and structural lung disease in infants and young children with cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 917 - 922

**Chang MT., Patel ZM.**

Update on long-term outcomes for chronic rhinosinusitis in cystic fibrosis  
*Current Opinion in Otolaryngology & Head and Neck Surgery* 2020; 28: 46 - 51

**Davies G., Stanojevic S., Raywood E., Duncan JA., Stocks J., Lum S., Bush A., Viviani L., Wade A., Calder A., Owens CM., Goubau C., Carr SB., Bossley CJ., Pao CE., Aurora P.**

An observational study of the lung clearance index throughout childhood in cystic fibrosis: early years matter  
*European Respiratory Journal* 2020; 56: 4:2000006

**Flynn S., Reen FJ., Caparros-Martin JA., Woods DF., Peplies J., Ranganathan SC., Stick SM., O'Gara F.**

Bile Acid Signal Molecules Associate Temporally with Respiratory Inflammation and Microbiome Signatures in Clinically Stable Cystic Fibrosis Patients  
*Microorganisms* 2020; 8: 11:1741

**Horati H., Janssens HM., Margaroli C., Veltman M., Stolarczyk M., Kilgore MB., Chou J., Peng LM., Tiddens HAMW., Chandler JD., Tirouvanziam R., Scholte BJ.**

Airway profile of bioactive lipids predicts early progression of lung disease in cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 902 - 909

**Ishak A., Stick SM., Turkovic L., Ranganathan SC., King L., Harrison J., Sly PD., Caudri D., Schultz A.**

BAL Inflammatory Markers Can Predict Pulmonary Exacerbations in Children With Cystic Fibrosis  
*Chest* 2020; 158: 2314 - 2322

**Jagpal SK., Jobanputra AM., Ahmed OH., Santiago TV., Ramagopal M.**

Sleep-disordered breathing in cystic fibrosis  
*Pediatric Pulmonology* 2021; 56:

**Karimizadeh A., Vali M., Modaresi M.**

Multichannel lung sound analysis to detect severity of lung disease in cystic fibrosis  
*Biomedical Signal Processing and Control* 2021; 64: ArtNo: 102266

**Kinghorn B., McNamara S., Genatossio A., Sullivan E., Siegel M., Bauer L., Clem C., Johnson RC., Davis M., Griffiths A., Wheeler W., Johnson K., Davis SD., Leigh MW., Rosenfeld M., Pittman J.**

Comparison of Multiple Breath Washout and Spirometry in Children with Primary Ciliary Dyskinesia and Cystic Fibrosis and Healthy Controls  
*Annals of the American Thoracic Society* 2020; 17: 1085 - 1093

**Logie K., Welsh L., Ranganathan SC.**

Telehealth spirometry for children with cystic fibrosis  
*Archives of Disease in Childhood* 2020; 105: 1203 - 1205

**McLeod C., Wood J., Schultz A., Norman R., Smith S., Blyth CC., Webb S., Smyth AR., Snelling TL.**

Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: A systematic review  
*Journal of Cystic Fibrosis* 2020; 19: 858 - 867

**Muston HN., Perrem L., Davis MD., Ratjen F., Ren CL.**

The remaining barriers to normalcy in CF: Advances in assessment of CF lung disease  
*Pediatric Pulmonology* 2021; 56:

**Nissenbaum C., Davies G., Horsley A., Davies JC.**

Monitoring early stage lung disease in cystic fibrosis  
*Current Opinion in Pulmonary Medicine* 2020; 26: 671 - 678

**Perrissin-Fabert M., Stheneur C., Veilleux-Lemieux M., Taddeo D., Marcotte JE., Boutin A., Nguyen LA., Frappier JY.**  
Hormonal Contraception Effects on Pulmonary Function in Adolescents with Cystic Fibrosis  
*Journal of Pediatric and Adolescent Gynecology* 2020; 33: 681 - 685

**Piva TC., Luft C., Antunes KH., Marostica PJC., Pinto LA., Donadio MVF.**

Extracellular DNA in sputum is associated with pulmonary function and hospitalization in patients with cystic fibrosis  
*Respiratory Medicine* 2020; 172: ArtNo: 106144

**Ring AM., Carlens J., Bush A., Castillo-Corullon S., Fasola S., Gaboli MP., Griese M., Koucky V., La Grutta S., Lombardi E., Proesmans M., Schwerk N., Snijders D., Nielsen KG., Buchvald F.**  
Pulmonary function testing in children's interstitial lung disease  
*European Respiratory Review* 2020; 29: 157:200019

**Ronan P., Mian A., Carr SB., Madge SL., Lorenc A., Robinson N.**  
Learning to breathe with Tai Chi online - qualitative data from a randomized controlled feasibility study of patients with cystic fibrosis  
*European Journal of Integrative Medicine* 2020; 40: ArtNo: 101229

**Skov L., Green K., Stanojevic S., Jensen R., Buchvald F., Ratjen F., Nielsen KG.**  
Lung compartment analysis assessed from N-2 multiple-breath washout in children with cystic fibrosis  
*Pediatric Pulmonology* 2020; 55: 1671 - 1680

**Smith LJ., Horsley A., Bray J., Hughes PJC., Biancardi A., Norquay G., Wildman M., West N., Marshall H., Wild JM.**  
The assessment of short- and long-term changes in lung function in cystic fibrosis using Xe-129 MRI  
*European Respiratory Journal* 2020; 56: 6:2000441

**Stahl M., Joachim C., Kirsch I., Uselmann T., Yu Y., Alfeis N., Berger C., Minso R., Rudolf I., Stolpe C., Bovermann X., Liboschik L., Steinmetz A., Tennhardt D., Dorfler F., Rohmel J., Unorji-Frank K., Ruckes-Nilges C., et al**  
Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases  
*ERJ Open Research* 2020; 6: 4:00408-2020

**Stanford G., Davies JC., Usmani O., Banya W., Charman S., Jones M., Simmonds NJ., Bilton D.**  
Investigating outcome measures for assessing airway clearance techniques in adults with cystic fibrosis: protocol of a single-centre randomised controlled crossover trial  
*BMJ Open Respiratory Research* 2020; 7: 1:e000694

**Steffen LM., Pezzin LS., Sulis N., Steffen N., Pinto LA.**  
Upper Airway Findings and Markers of Lung Disease Progression in Patients with Cystic Fibrosis  
*International Archives of Otorhinolaryngology* 2020; 24: E434 - E437

**Svedberg M., Gustafsson P., Tiddens H., Imberg H., Pivodic A., Lindblad A.**  
Risk factors for progression of structural lung disease in school-age children with cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 910 - 916

**Taylor SL., Leong LEX., Ivey KL., Wesselingh S., Grimwood K., Wainwright CE., Rogers GB.**  
Total bacterial load, inflammation, and structural lung disease in paediatric cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: 923 - 930

**Wang C., Johnson R., Horani S., Brown C., Mitchell R., Shah G.**  
Chronic rhinosinusitis and endoscopic sinus surgery in children admitted for pulmonary exacerbations of cystic fibrosis  
*International Journal of Pediatric Otorhinolaryngology* 2021; 140: ArtNo: 110548

**Wheelock CE., Strandvik B.**  
Abnormal n-6 fatty acid metabolism in cystic fibrosis contributes to pulmonary symptoms  
*Prostaglandins Leukotrienes and Essential Fatty Acids* 2020; 160: ArtNo: 102156

## Radiology

**Goralski JL., Stewart NJ., Woods JC.**  
Novel imaging techniques for cystic fibrosis lung disease  
*Pediatric Pulmonology* 2021; 56:

**Tiddens HAWM., Andrinopoulou ER., McIntosh J., Elborn JS., Kerem E., Bouma N., Bosch J., Kemner-van de Corput M.**  
Chest computed tomography outcomes in a randomized clinical trial in cystic fibrosis: Lessons learned from the first ataluren phase 3 study  
*PLoS One* 2020; 15: 11:e0240898

**Vass L., Fisk M., Lee S., Wilson FJ., Cheriyan J., Wilkinson I.**  
Advances in PET to assess pulmonary inflammation: A systematic review  
*European Journal of Radiology* 2020; 130: ArtNo: 109182

## Screening

**Audrezet MP., Munck A.**  
Newborn screening for CF in France: An exemplary national experience  
*Archives de Pediatrie* 2020; 27:

**Cacciatore P., Visser LA., Buyukkaramikli N., van der Ploeg CPB., van den Akker-van Marle ME.**  
The Methodological Quality and Challenges in Conducting Economic Evaluations of Newborn Screening: A Scoping Review  
*International Journal of Neonatal Screening* 2020; 6: 4:94

**Castaldo A., Cimbalo C., Castaldo RJ., D'Antonio M., Scorza M., Salvadori L., Sepe A., Raia V., Tosco A.**  
Cystic Fibrosis-Screening Positive Inconclusive Diagnosis: Newborn Screening and Long-Term Follow-Up Permits to Early Identify Patients with CFTR-Related Disorders  
*Diagnostics* 2020; 10: 8:570

**Castells EM., Sanchez A., Frometa A., Mokdse Y., Ozunas N., Licourt T., Arteaga AL., Silva E., Collazo T., Rodriguez F., Martin O., Espinosa M., del Rio L., Perez PL., Morejon G., Almira C., Nunez Z., Melchor A., Gonzalez EC.**  
Pilot study for cystic fibrosis neonatal screening: the Cuban experience  
*Clinical Chemistry and Laboratory Medicine* 2020; 58: 1857 - 1864

**Davies G., Thia LP., Stocks J., Bush A., Hoo AF., Wade A., Nguyen TTD., Brody AS., Calder A., Klein NJ., Carr SB., Wallis C., Suri R., Pao CS., Ruiz G., Balfour-Lynn IM.**  
Minimal change in structural, functional and inflammatory markers of lung disease in newborn screened infants with cystic fibrosis at one year  
*Journal of Cystic Fibrosis* 2020; 19: 896 - 901

**Farrell MH., Sims AM., Kirschner AL., Farrell PM., Tarini BA.**  
Vulnerable Child Syndrome and Newborn Screening Carrier Results for Cystic Fibrosis or Sickle Cell  
*Journal of Pediatrics* 2020; 224: 44

**Garcia SP., Galera RML., Soria JLM., Ramirez AA., de Aledo-Castillo JMG., Rubio AR., Viedma BP., Ministrál LA., Garcia-Villoria J.**  
Impact of the inclusion of second-tier tests in the newborn screening program of Catalonia and in other international programs  
*Revista Espanola de Salud Publica* 2020; 94: ArtNo: e202012

**Maciel LMZ., Magalhaes PKR., Del Ciampo IRL., de Sousa MLB., Fernandes MIM., Sawamura R., Bittar RR., de Molfetta GA., da Silva WA.**  
The first five-year evaluation of cystic fibrosis neonatal screening program in Sao Paulo State, Brazil  
*Cadernos de Saude Publica* 2020; 36: 10:e00049719

**Naehrlich L.**  
The Changing Face of Cystic Fibrosis and Its Implications for Screening  
*International Journal of Neonatal Screening* 2020; 6: 3:54

## Therapy (Non Antimicrobial)

**Ballmann M., Prinz N., Glass A., Holl R.**

Comment on "Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients"

*Journal of Cystic Fibrosis* 2020; 19: 839

**Berkers G., van der Meer R., van Mourik P., Vonk AM., Kruisselbrink E., Suen SW., Heijerman HG., Majoor CJ., Koppelman GH., Roukema J., Janssens HM., de Rijke YB., Kemper EM., Beekman JM., van der Ent CK., de Jonge HR.**  
Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

*Journal of Cystic Fibrosis* 2020; 19: 955 - 961

**Birket SE., Davis JM., Fernandez-Petty CM., Henderson AG., Oden AM., Tang LP., Wen H., Hong J., Fu LW., Chambers A., Fields A., Zhao G., Tearney GJ., Sorscher EJ., Rowe SM.**

Ivacaftor Reverses Airway Mucus Abnormalities in a Rat Model Harboring a Humanized G551D-CFTR

*American Journal of Respiratory and Critical Care Medicine* 2020; 202: 1271 - 1282

**Chang KH., Moon SH., Yoo SK., Park BJ., Nam KC.**

Aerosol Delivery of Dornase Alfa Generated by Jet and Mesh Nebulizers

*Pharmaceutics* 2020; 12: ArtNo 721

**Dave K., Dobra R., Scott S., Saunders C., Matthews J., Simmonds NJ., Davies JC.**

Entering the era of highly effective modulator therapies

*Pediatric Pulmonology* 2021; 56:

**De Boeck K., Lee T., Amaral M., Drevinek P., Elborn JS., Fajac L., Kerem E., Davies JC.**

Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view

*Journal of Cystic Fibrosis* 2020; 19: 688 - 695

**Devereux G., Wrolstad D., Bourke SJ., Daines CL., Doe S., Dougherty R., Franco R., Innes A., Kopp BT., Lascano J., Layish D., MacGregor G., Murray L., Peckham D., Lucidi V., Lovie E., Robertson J., Fraser-Pitt DJ., O'Neil DA.**

Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial

*PLoS One* 2020; 15: 12:e0242945

**Dolgin E.**

In utero intervention to stem the damage of cystic fibrosis

*Nature* 2020; 583: S6 - S7

**Donaldson SH., Samulski TD., LaFave C., Zeman K., Wu JH., Trimble A., Ceppe A., Bennett WD., Davis SD.**

A four week trial of hypertonic saline in children with mild cystic fibrosis lung disease: Effect on mucociliary clearance and clinical outcomes

*Journal of Cystic Fibrosis* 2020; 19: 942 - 948

**Dougherty PG., Wellmerling JH., Koley A., Lukowski JK., Hummon AB., Cormet-Boyaka E., Pei DH.**

Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis

*Journal of Medicinal Chemistry* 2020; 63: 15773 - 15784

**Egan ME.**

Emerging technologies for cystic fibrosis transmembrane conductance regulator restoration in all people with CF

*Pediatric Pulmonology* 2021; 56:

**Eschenhagen P., Schwarz C.**

Therapy of Cystic Fibrosis - new Drugs give Hope

*Deutsche Medizinische Wochenschrift* 2020; 145: 1486 - 1489

**Fajac L., Girodon E.**

Genomically-guided therapies: A new era for cystic fibrosis

*Archives de Pediatrie* 2020; 27:

**Fonseca C., Bicker J., Alves G., Falcao A., Fortuna A.**

Cystic fibrosis: Physiopathology and the latest pharmacological treatments

*Pharmacological Research* 2020; 162: ArtNo: 105267

**Gifford AH., Mayer-Hamblett N., Pearson K., Nichols DP.**

Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy

*Journal of Cystic Fibrosis* 2020; 19: 762 - 767

**Goss CH., Jain R., Seibold W., Picard AC., Hsu MC., Gupta A., Fajac L.**

An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CF (TM) 1

*ERJ Open Research* 2020; 6: 4:00395-2020

**Graeber SY., van Mourik P., Vonk AM., Kruisselbrink E., Hirtz S., van der Ent CK., Mall MA., Beekman JM.**

Comparison of Organoid Swelling and In Vivo Biomarkers of CFTR Function to Determine Effects of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation

*American Journal of Respiratory and Critical Care Medicine* 2020; 202: 1589 - 1592

**Gramegna A., Contarini M., Aliberti S., Casciaro R., Blasi F., Castellani C.**

From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis

*International Journal of Molecular Sciences* 2020; 21: 16:5882

**Guichard MJ., Wilms T., Mahri S., Patil HP., Hoton D., Ucakar B., Vanvarenberg K., Cheou P., Beka M., Marbaix E., Leal T., Vanbever R.**

PEGylation of Recombinant Human Deoxyribonuclease I Provides a Long-Acting Version of the Mucolytic for Patients with Cystic Fibrosis

*Advanced Therapeutics* 2020; 11: ArtNo: 585243

**Guimbellot JS., Ryan KJ., Anderson JD., Liu ZY., Kersh L., Esther CR., Rowe SM., Acosta EP.**

Variable cellular ivacaftor concentrations in people with cystic fibrosis on modulator therapy

*Journal of Cystic Fibrosis* 2020; 19: 742 - 745

**Keown K., Brown R., Doherty DF., Houston C., McKelvey MC., Creane S., Linden D., McAuley DF., Kidney JC., Weldon S., Downey DG., Taggart CC.**

Airway Inflammation and Host Responses in the Era of CFTR Modulators

*International Journal of Molecular Sciences* 2020; 21: 17:6379

**Lai SL., Mazzaferro S., Mitterhofer AP., Tinti F., Bonci E., Giovannetti A., Casella C., Perrotta AM., Bagordo D., Murciano M., Galani A., Celani C., Troiani P., Cimino G., Palange P.**

Adult Patients Affected by Cystic Fibrosis in Therapy with Cystic Fibrosis Transmembrane Regulator Modulators and Lung Transplant: Renal Function, Metabolic and Nutritional Status

*Journal of Nutrition and Metabolism* 2020; 2020: ArtNo: 6183969

**Lee TNG., Cholon DM., Quinney NL., Gentsch M., Esther CR.**

Accumulation and persistence of ivacaftor in airway epithelia with prolonged treatment

*Journal of Cystic Fibrosis* 2020; 19: 746 - 751

**Liessi N., Pesce E., Braccia C., Bertozzi SM., Giraud A., Bandiera T., Pedemonte N., Armirotti A.**

Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta

*JCI Insight* 2020; 5: 16:e138722

**Limberis MP.**

Breathing Easier: Molecular Therapeutics for Cystic Fibrosis

*Human Gene Therapy* 2020; 31: 905 - 906

**Mahri S., Hardy E., Wilms T., De Keersmaecker H., Braeckmans K., De Smedt S., Bosquillon C., Vanbever R.**

PEGylation of recombinant human deoxyribonuclease I decreases its transport across lung epithelial cells and uptake by macrophages

*International Journal of Pharmaceutics* 2021; 593: ArtNo: 120107

**Mayer-Hamblett N., Van Koningsbruggen-Rietschel S., Nichols DP., VanDevanter DR., Davies JC., Lee T., Durmowicz AG., Ratjen F., Konstan MW., Pearson K., Bell SC., Clancy JP., Taylor-Cousar JL., De Boeck K., Donaldson SH., Downey DG., et al**

Building global development strategies for cf therapeutics during a transitional CFTR modulator era  
*Journal of Cystic Fibrosis* 2020; 19: 677 - 687

**McCrary MS., Quinney NL., Cholon DM., Boyles SE., Jensen TJ., Aleksandrov AA., Donaldson SH., Noone PG., Gentsch M.**  
Personalised medicine for non-classic cystic fibrosis resulting from rare CFTR mutations  
*European Respiratory Journal* 2020; 56: 1:2000062

**Misgault B., Chatron E., Reynaud Q., Touzet S., Abely M., Melly L., Dominique S., Troussier F., Ronsin-Pradel O., Gerardin M., Mankikian J., Cosson L., Chiron R., Bounyar L., Porzio M., Durieu I., Weiss L., Kessler R., Kessler L.**  
Effect of one-year lumacaftor-ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients  
*Journal of Cystic Fibrosis* 2020; 19: 712 - 716

**Munck A., Kerem E., Ellemunter H., Campbell D., Wang LT., Ahluwalia N., Owen CA., Wainwright C.**  
Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations  
*Journal of Cystic Fibrosis* 2020; 19: 962 - 968

**Nichols AL., Davies JC., Jones D., Carr SB.**  
Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor  
*Paediatric Respiratory Reviews* 2020; 35: 99 - 102

**Nickolaus P., Jung B., Sabater J., Constant S., Gupta A.**  
Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis  
*ERJ Open Research* 2020; 6: 4:00429-2020

**O'Hare BJ., Kim CSJ., Hamrick SK., Ye D., Tester DJ., Ackerman MJ.**  
Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes  
*Circulation-genomic and Precision Medicine* 2020; 13: 466 - 475

**Paterson SL., Barry PJ., Horsley AR.**  
Tezacaftor and ivacaftor for the treatment of cystic fibrosis  
*Expert Review of Respiratory Medicine* 2020; 14: 15 - 30

**Perrem L., Ratjen F.**  
Designing Clinical Trials for Anti-Inflammatory Therapies in Cystic Fibrosis  
*Frontiers in Pharmacology* 2020; 11: ArtNo: 576293

**Perveen S., Chaudhry MR., AlBabtain S., Amreen S., Brar SK., Zeb M., Khan S.**  
How Clinically Efficient Are Lumacaftor/Ivacaftor for Cystic Fibrosis Patients: An Updated Literature Review  
*Cureus* 2020; 12: 12:e12251

**Petrocheilou A., Kaditis AG., Troupi E., Loukou I.**  
Nebulizer Care and Inhalation Technique in Children with Cystic Fibrosis  
*Children* 2020; 7: 10:153

**Qiu F., Habgood M., Schneider-Futschik EK.**  
The Balance between the Safety of Mother, Fetus, and Newborn Undergoing Cystic Fibrosis Transmembrane Conductance Regulator Treatments during Pregnancy  
*ACS Pharmacology & Translational Science* 2020; 3: 835 - 843

**Reyes-Ortega F., Qiu F., Schneider-Futschik EK.**  
Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method  
*ACS Pharmacology & Translational Science* 2020; 3: 987 - 996

**Rotolo SM., Duehlmeyer S., Slack SM., Jacobs HR., Heckman B.**  
Testicular pain following initiation of elexacaftor/tezacaftor/ivacaftor in males with cystic fibrosis  
*Journal of Cystic Fibrosis* 2020; 19: E39 - E41

**Rowe SM., Jones I., Dransfield MT., Haque N., Gleason S., Hayes KA., Kulmatycki K., Yates DP., Danahay H., Gosling M., Rowlands DJ., Grant SS.**  
Efficacy and Safety of the CFTR Potentiator Icatincaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial  
*International Journal of Chronic Obstructive Pulmonary Disease* 2020; 15: 2399 - 2409

**Sagel SD., Khan U., Heltshe SL., Clancy JP., Borowitz D., Gelfond D., Donaldson SH., Moran A., Ratjen F., VanDalfsen JM., Rowe SM.**  
Clinical Effectiveness of Lumacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR A Clinical Trial  
*Annals of the American Thoracic Society* 2021; 18: 75 - 83

**Salvatore D., Terlizzi V., Francalanci M., Taccetti G., Messori B., Biglia C., Pisi G., Calderazzo MA., Caloiero M., Pizzamiglio G., Majo F., Cresta F., Leonetti G., De Venuto D.**  
Ivacaftor improves lung disease in patients with advanced CF carrying CFTR mutations that confer residual function  
*Respiratory Medicine* 2020; 171: ArtNo: 106073

**Sanders DB., Chmiel JF.**  
Drug development for cystic fibrosis  
*Pediatric Pulmonology* 2021; 56:

**Shaw M., Khan U., Clancy JP., Donaldson SH., Sagel SD., Rowe SM., Ratjen F.**  
Changes in LCI in F508del/F508del patients treated with lumacaftor/ivacaftor: Results from the prospect study  
*Journal of Cystic Fibrosis* 2020; 19: 931 - 933

**Somayaji R., Nichols DP., Bell SC.**  
Cystic fibrosis - Ten promising therapeutic approaches in the current era of care  
*Expert Opinion On Investigational Drugs* 2020; 29: 1107 - 1124

**Tetard C., Mittaine M., Bui S., Beaufile F., Maumus P., Fayon M., Burgel PR., Lamireau T., Delhaes L., Mas E., Enaud R.**  
Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis  
*Journal of Pediatric Gastroenterology and Nutrition* 2020; 71: 778 - 781

**Wherry K., Williamson I., Chapman RH., Kuntz KM.**  
Cost-Effectiveness of Ivacaftor Therapy for Treatment of Cystic Fibrosis Patients With the G551D Gating Mutation  
*Value in Health* 2020; 23: 1332 - 1339

## Transplantation

**Antonczyk R., Urlik M., Latos M., Pandel A., Gaweda M., Necki M., Kret M., Przybylowski P., Zembala M., Ochman M., Stacel T.**  
Single Lung Transplantation With Concomitant Cardiac Surgery in a Patient With Cystic Fibrosis: A Case Report  
*Transplantation Proceedings* 2020; 52: 2554 - 2557

**David V., Perrin A., Le Rhun A., Pougheon-Bertrand D., Kanaan R., Grenet D., Moret L.**  
Provision of information on transplantation to cystic fibrosis patients and their relatives: Overview of French practices and recommendations  
*Respiratory Medicine and Research* 2020; 10: 10:e037081

**Ladores S., Bray LA., Brown J., Corcoran J., Jordan J., Buczek E.**  
Retropharyngeal abscess in a post-lung transplant cystic fibrosis patient with prior cervical fusion: a case study  
*BMC Pulmonary Medicine* 2020; 20: 1:224

**Lehr CJ., Fink AK., Skeans M., Faro A., Fernandez G., Dasenbrook E., Valapour M.**  
Impact of Socioeconomic Position on Access to the US Lung Transplant Waiting List in a Matched Cystic Fibrosis Cohort  
*Annals of the American Thoracic Society* 2020; 17: 1384 - 1392

**Lupi A., Barbiero G., Battistel M., Ferrarese A., Loy M., Feltracco P., Stramare R., Burra P., Senzolo M.**

Transjugular intrahepatic portosystemic shunt in non-cirrhotic portal hypertension related to cystic fibrosis in a lung transplant patient  
*Journal of Cystic Fibrosis* 2020; 19: E45 - E47

**Renner S., Nachbaur E., Jaksch P., Dehlink E.**

Update on Respiratory Fungal Infections in Cystic Fibrosis Lung Disease and after Lung Transplantation  
*Journal of Fungi* 2020; 6: 4:381

**Roquet G., Maury JM., Mabrut JY., Flamens C., Senechal A., Mornex JF., Tronc F.**

Combined Single Lung and Liver Transplantation in a Cystic Fibrosis Patient With Previous Contralateral Pneumonectomy: A Case Report  
*Transplantation Proceedings* 2020; 52: 2820 - 2823

**Sethi J., Bugajski A., Patel KN., Davis NM., Wille KM., Qureshi MR., Banday MM., Lin ML., Emami V., Weill D., Tumin D., Hayes D., Sharma NS.**

Recipient Age Impacts Long-Term Survival in Adult Subjects with Cystic Fibrosis after Lung Transplantation  
*Annals of the American Thoracic Society* 2021; 18: 44 - 50

**Zhang T., Price MB., Bravo N., Villarreal JA., Kueht ML., Vierling JM., Cotton R., Galvan T., O'Mahony CA., Goss JA., Rana A.**

Combined Lung-Liver and Delayed Kidney Transplantation for Cystic Fibrosis Clinical Approach and Outcome: A Case Report  
*Transplantation Proceedings* 2020; 52: 2824 - 2826

## **Urology**

**Gauthier S., Pranke I., Jung V., Martignetti L., Stoven V., Nguyen-Khoa T., Semeraro M., Hinzpeter A., Edelman A., Guerrero IC., Sermet-Gaudelus I.**

Urinary Exosomes of Patients with Cystic Fibrosis Unravel CFTR-Related Renal Disease  
*International Journal of Molecular Sciences* 2020; 21: 18:6625